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1. Introduction 
1.1 Oxidative stress 
Oxygen was discovered by the Swedish scientist Carl Wilhelm Scheele in 1777. The 
quotation by Neil Young “The same thing that makes you live can kill you in the 
end” fits well with the functions of oxygen in aerobes. Oxygen is both essential and 
toxic to aerobes. The essentiality lies in the energy production via a class of chemical 
reactions called as reduction-oxidation or redox reactions. The toxicity is due to a 
number of free radicals and other reactive oxygen- and nitrogen species (ROS/RNS) 
produced during these normal cellular redox reactions as listed in Table 1. 
Table 1 Examples of ROS and RNS 
Free radicals Non-radicals 
Superoxide, O2•– Hydrogenperoxide, 
H2O2
Dinitrogen tetraoxide, 
N2O4
Hydroxyl, OH• Hypochlorous acid, 
HOCl
Peroxynitrite, ONOO-
Peroxyl, RO2• Ozone, O3 Peroxynitrous acid, 
ONOOH
Alloxyl, RO• Nitronium ion, NO2+ Nitroxyl anion, NO-
Hydroperoxyl, HO2• Singlet oxygen, 1O2 Nitrosyl cation, NO+
Nitric oxide, NO•   
Nitrogen dioxide, 
NO2•
Dinitrogen trioxide, 
N2O3
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The main endogenous source for the production of ROS in eukaryotes is 
mitochondria via electron transport chain. The reduction of oxygen to water in 
mitochondria requires four electrons. Even under ideal conditions, there is leakage of 
electrons and 1-3% O2 undergoes an incomplete singlet reduction producing reactive 
species especially superoxide anion (O2•–) (1). Other potential endogenous sources 
are cytochrome P- 450 (phase 1 detoxification reactions), xanthine oxidase (purine 
degradation pathway), microsomes and peroxisomes (produce mainly hydrogen 
peroxide H2O2) , and inflammatory cell activation (1). Besides ROS, other reactive 
species like RNS are also produced. The most important source of nitrogen for the 
generation of RNS in vivo is nitric oxide (NO•) (2). It is known to be a product of the 
catalytic action of the nitric oxide synthase enzyme family on L-arginine (2). Recent 
evidence also suggests that it can be generated by reduction of nitrite, which can arise 
in the body by ingestion or from bacterial metabolism (2). Although nitric oxide 
(NO•) is not highly reactive with biological molecules it reacts rapidly with other 
oxygen radicals to generate highly damaging RNS such as peroxynitrite (ONOO-),
nitrogen dioxide radical (NO2•) and dinitrogen trioxide (N2O3) (2) (Table 1). 
Enhanced formation of ROS/RNS also occurs as a consequence of diseases and from 
exogenous factors like tobacco smoke, environmental pollutants, drugs, ethanol and 
radiation (3). The reactivity and specificity of both ROS and RNS vary, hydroxyl 
(OH•) being the most reactive free radical with a half life of approximately 10-9
seconds (4). 
The reactive species produced can both be useful and harmful. Among their useful 
functions, they are involved in pathogen defence, apoptosis, cell signalling pathways 
and regulation of transcription factors (5-7).  .
The harmful effects of ROS/RNS are due to their non-enzymatic oxidation of various 
important cellular components like lipids, proteins and DNA. Lipid peroxidation 
occurs mostly in cellular membranes and low-density lipoproteins (LDL). The 
oxidation of lipids in plasma membranes alters their physical properties thereby 
changing their biological function. Oxidation of LDL is considered as one of the 
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factors contributing to atherosclerosis leading to cardiovascular disease (8). Protein 
oxidation leads to loss of function or premature degradation in several proteins 
thereby resulting in functional changes modulating cellular metabolism. Cataracts are 
thought due to photooxidation of lens proteins resulting in protein damage, 
accumulation, aggregation and precipitation in the lens (9). DNA oxidation can lead 
to gene mutation, and thus abnormal protein synthesis, alteration in gene expression, 
apoptosis and cell death. Oxidatively modified DNA may also play a role in 
carcinogenesis (10).
In order to counteract these highly reactive species, eukaryotic cells have developed a 
complex system of both enzymatic and non-enzymatic compounds, referred to as 
endogenous antioxidant defence. A critical balance is maintained between generation 
of ROS/RNS and the antioxidant defence. When there is an imbalance in the favour 
of ROS/RNS, either due to high production of ROS/RNS or due to impairment of 
antioxidant defence, these reactive species interfere with the normal function of 
ROS/RNS, and non-enzymatically oxidize and alter the structure and function of 
several cellular components such as lipids, proteins and DNA as described above. An 
accumulation of these oxidative damages will occur over time and result in oxidative 
stress. Oxidative stress is, thus, defined as “a condition that is characterized by 
accumulation of non-enzymatic oxidative damage to molecules that threaten the 
normal function of the cell or the organism” (3).  
Compelling evidence has emerged in the last two decades demonstrating that 
oxidative stress is intimately involved in the pathophysiology of many types of 
diseases. Oxidative stress is now thought to make significant contribution to all 
inflammatory diseases (e.g. arthritis, vasculitis, glomerulonephritis, systemic lupus 
erythematosus, adult respiratory distress syndrome), ischemic diseases (heart disease, 
stroke, intestinal ischemia), cancer, hemochromatosis, acquired immunodeficiency 
syndrome (AIDS), emphysema, gastric ulcers, hypertension and preeclampsia, 
neurologic diseases (multiple sclerosis, Alzheimer’s disease, Parkinson disease, 
amyotrophic lateral sclerosis, muscular dystrophy), alcoholism, smoking-related 
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diseases, and many others as reviewed by McCord et al. (11). Additionally, a slow 
and steady accumulation of oxidative damage has also been considered as the major 
theory of aging (12). 
1.2 Defence system against oxidative damage  
As mentioned above, in order to minimize the generation and counterbalance the 
damaging effects of reactive species, eukaryotes have developed a comprehensive 
defence system. The defence system comprises of both enzymatic and non-enzymatic 
components, which works at different molecular aspects.  
Preventive antioxidants suppress the formation and decrease the reactivity of reactive 
species. The enzymes involved in this process include superoxide dismutase, catalase, 
glutathione peroxidase, glutathione reductase, peroxiredoxins and thioredoxin 
reductase. The non enzymatic components include polypeptides like thioredoxins, 
glutaredoxins and sulfiredoxins; metal binding proteins like transferrin, albumin; low 
molecular weight antioxidants like glutathione, uric acid; dietary antioxidants like 
vitamin E, ascorbic acid, carotenoids and polyphenols. 
Another aspect in this defence is the repairing process and includes repair enzymes, 
which repair the damage and reconstitute membranes and DNA, for example lipase, 
DNA repair enzymes and transferases. 
The defence system mentioned above could be called as “antioxidant defence 
system” since an antioxidant defined by Halliwell is any substance that delays, 
prevents or removes oxidative damage to a target molecule (13). A brief description 
of some of the endogenous and dietary antioxidants is given below. 
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1.2.1 Endogenous antioxidants 
Antioxidant enzymes 
The major enzymatic antioxidants present in eukaryotes are superoxide dismutase, 
catalase, glutathione peroxidase, glutathione reductase, peroxiredoxins and 
thioredoxin reductase. 
Superoxide dismutase 
Superoxide dismutase (SOD) was first discovered by McCord and Fridovich in 1969 
(14). SOD catalyses the dismutation of two superoxide anions (O2•–) to oxygen and 
less potent hydrogen peroxide (H2O2) in the following reaction:
It is a pseudo first order reaction with rate constant of magnitude 109 M-1S-1 (15). 
Three major forms of SODs (cytosolic CuZnSOD, mitochondrial MnSOD and 
extracellular SOD) are present in animal cells based on their structure, localisation, 
inducibility and metal ion requirement. SOD containing other transition metals like 
FeSOD, Fe/MnSOD and NiSOD are present in some bacteria (13). All SODs 
destroys O2•– by successive oxidation and reduction of the transition metal ion at the 
active site. MnSOD is considered to be one of the most important antioxidant 
components of a cell and is largely located in mitochondria (15). MnSOD is a 
homotetrameric enzyme with Mn (III) at its active centre. CuZnSOD, a homodimeric 
protein, is located mainly in cytosol and requires both Cu (II) and Zn (II) at its active 
site. Cu (II) is essential for the enzymes catalytical activity, and Zn (II) imparts 
stability to the protein structure (15). Extracellular SOD, a tetrameric glycoprotein, 
also contains Cu (II) and Zn (II) and is found in the interstitial spaces of tissues and 
extracellular fluids, accounting for the majority of the SOD activity in plasma, lymph 
and synovial fluid (16).
Reports involving SOD knock outs have revealed that MnSOD is essential for life 
and mice deficient in MnSOD gene die within 10-21 days after birth from 
O2•– + O2•– + 2H+ H2O2 + O2
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cardiomyopathy, metabolic acidosis and neurodegeneration (17;18). Mice lacking 
cytosolic CuZnSOD, however, appear normal when they are young, but with age they 
develop neurological damage, muscle wasting, hearing loss and cancers (especially 
liver cancer) at accelerated rates. They also have reproductive problems and show 
impaired vascular reactivity (13).
Catalase
Catalase was named by Loew in 1901 (14). The enzyme consists of four protein 
subunits, each containing a heme group [Fe(III)-protoporphyrin] bound to its active 
site (14). Catalase decomposes hydrogen peroxide (H2O2) into water and oxygen as 
shown in the following equation: 
Catalase is ubiquitous to most aerobic cells. In animals, catalase is present in all 
major body organs and is especially concentrated in the liver and erythrocytes (14). 
At the subcellular level, catalase is found in peroxisomes (80%) and cytosol (20%) 
(14). Mice lacking catalase grow normally and show no obvious abnormalities, 
although their tissues showed a retarded rate in decomposing extracellular H2O2 (19).
Additionally, these mice are more susceptible to trauma induced dysfunction in brain 
mitochondria (19). 
Glutathione peroxidase 
Glutathione peroxidase (GPx) was first described by Mills in 1957 (14). The enzyme 
reduces hydrogen peroxide (H2O2) to water with oxidation of GSH to glutathione 
disulphide (GSSG) in the following reaction: 
GPx are a family of selenium dependent and independent enzymes. They are widely 
distributed in animal tissues and are less common in plants or bacteria. The GPx 
enzymes are mostly specific for GSH as a hydrogen donor. They can however act on 
2H2O2 2H2O + O2
H2O2 + 2GSH GSSG + 2H2O
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other peroxides than hydrogen peroxide (H2O2). Four types of selenium dependent 
GPx exist,  cytosolic/mitochondrial GPx (GPx1), cytosolic GPx (GPx2), extracellular 
GPx (GPx3 a glycoprotein) and phospholipid hydroperoxide GPx (GPx4) (16). GPx1 
is present mainly in erythrocytes, kidney and liver; GPx2 in gastrointestinal tract; 
GPx3 in kidney and extracellular fluids like plasma, milk, seminal fluid, amniotic 
fluid, aqueous humor of the eye and lung lining fluid; Gpx4 is present ubiquitous but 
highest in renal epithelial cells and testis (13;16). GPx2 may serve to metabolize 
peroxides in ingested food lipids as well as generated during lipid peroxidation in the 
intestine itself (13). GPx4, located both in cytosol and the membrane fraction, has the 
unique ability to reduce not only hydrogen peroxide (H2O2) and synthetic organic 
peroxides but also fatty acid and cholesterol hydroperoxides that are still esterified 
(13). It is less specific for GSH as a reductant and can also reduce thymine 
hydroperoxide (product of free radical attack on thymine in DNA) (20) suggesting a 
possible in the repair of DNA damage. The GPx5, expressed specifically in rodent 
epididymis is selenium independent (13).  
GPx1 knockout mice were healthy, fertile and showed normal phenotype (21). The 
animals, however, showed increased susceptibility particularly to ROS-mediated 
oxidative stress as compared to normal mice (22). Gpx4 homozygote knockout 
embryos die in utero by midgestation and were associated with a lack of normal 
structural compartmentalization (23). Gpx4 heterozygote displayed no morphological 
or behavioural abnormalities. The cell lines derived from heterozygotes were, 
however, sensitive to inducers of oxidative stress (23).
Glutathione reductase 
Glutathione reductase (GR) was initially observed by Hopkins and Elliott in 1931 and 
later isolated by Mann in 1932 (14). GR converts GSSG back to GSH in the 
following reaction: 
GSSG + NADPH + H+ 2GSH + NAD+
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GRs contain two subunits, each with flavin adenine dinucleotide (FAD) at its active 
site. The enzyme is found in cytosol and mitochondria which matches GPx 
distribution (14).
Peroxiredoxins and thioredoxin reductases 
Peroxiredoxins (Prx) are a family of nonseleno-peroxidases that reduce hydrogen 
peroxide (H2O2) and organic peroxides. They are homodimers and the redox 
reactions are dependent on cysteine at the active sites (13). Of the six mammalian 
members of this family, five (Prx1-Prx5) contain two conserved catalytic cysteines 
and utilize Trx as the reductant while Prx6 contains 1-cysteine and Trx is not 
involved in the reduction process (13;24). The Prx1, -2 and -6 occurs in cytosol 
whereas Prx3 only in mitochondria. The Prx4 form is found in the endoplasmic 
reticulum and extracellularly; and Prx5 in both mitochondria and peroxisomes (13). 
Thioredoxin reductase (TR) is a FAD containing flavoenzyme, and along with 
polypepetide thioredoxin plays a key role in maintaining proteins in their reduced 
states (15). These enzymes contain selenium (as selenocysteine) and show similarities 
to GR (13) 
Non-enzymatic antioxidants 
The non-enzymatic group includes low molecular weight antioxidants, polypeptides 
and metal binding proteins. 
Low-molecular weight antioxidants 
Several low molecular weight antioxidants are synthesized in vivo like GSH, lipoic 
acid, uric acid, taurine, bilrubin, D-keto acids, melatonin, coenzyme Q, histidine-
containing dipeptides, melanins, polyamines and plasmalogens. Among these 
antioxidants, GSH is one of the major cellular antioxidant. 
Glutathione
Glutathione (GSH) is one of the most abundant cellular antioxidant, present in 
millimolar concentrations in most prokaryotic and in all eukaryotic cells, providing 
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protection against reactive species. The antioxidant activity comes from the free thiol 
group of GSH, which is easily oxidized, non-enzymatically by electrophiles and other 
oxidants. GSH also serves critical roles in detoxification of electrophiles and oxidants 
through enzymatic reactions with GPx and conjugation reactions catalyzed by 
glutathione-S transferase (GST) (25). Additionally, GSH has a predominant role in 
regulation of cellular and subcellular redox state, for example through reactions with 
glutaredoxin and protein disulfide isomerases to organize a proper tertiary structure 
of proteins through thiol-disulfide exchange (26). Agents altering GSH concentration 
have shown to affect transcription of detoxification enzymes, cell proliferation and 
apoptosis (26-29). Other vital functions of GSH in animals have been reviewed 
thoroughly (25;26;30).
The level of total GSH (i.e. sum of all forms of GSH) in human tissues normally 
ranges from about 1 to 10 mM, being most concentrated in liver (around 10 mM), 
spleen, kidney and erythrocytes (13;25). The liver is the main site of GSH synthesis 
and a net supplier of circulatory GSH via an active export mechanism  (31;32). The 
intracellular concentrations of GSH and GSSG also vary considerably. Most of 
cellular GSH (85-90%) is present in cytosol with the rest in various subcellular 
organelles (25).
When the free thiol of GSH is oxidized, different oxidized forms of GSH may form 
including GSSG, mixed disulfides with free cysteine (GSSC) and protein bound GSH 
(PSSG, glutathionylation). The GSH/GSSG ratio is >10 under normal physiological 
conditions (25). During severe oxidative stress and detoxification reactions involving 
GSH, the concentration of free GSH may decrease and the concentration of GSSG 
may increase in the affected cells. However, during mild stress increased GSH 
concentrations (due to increased GSH synthesis) are often observed (33). Thus, many 
types of oxidative stress increased production of GSH through upregulation of J-
glutamylcysteine synthetase (GCS) (34). This upregulation provides protection from 
more severe stress and may be a critical feature of preconditioning and tolerance. 
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GSH synthesis 
The cellular GSH level is replenished either from i) de novo synthesis, ii) J-glutamyl
transpeptidase (GGT, also called J-glutamyl transferase) dependent recycling of 
extracellular GSH or other amino acids or iii) GSSG by NADPH-dependent GR. 
De novo synthesis of GSH 
The major determinant of GSH synthesis is the availability of cysteine and the level 
of the rate-limiting enzyme GCS, also called glutamate cysteine ligase (GCL). GSH 
is synthesised in the cell cytosol by the sequential actions of GCS and GSH 
synthetase (GS) (35).  GCS catalyzes formation of the dipeptide J-glutamylcysteine
(J-GC) from glutamate and cysteine, while GS catalyzes formation of the tripeptide 
GSH from J-GC and glycine. 
Mammalian GCS is a heterodimer comprising a heavy subunit (GCSh, 73 kDa) and 
light subunit (GCSl, 28 kDa) polypeptide each encoded by separate genes (36;37). 
Catalytical activity and GSH feedback inhibition are properties of the heavy subunit, 
but association with the catalytically inactive light or regulatory subunit can 
significantly influence its enzymatic activity by promoting high affinity for glutamate 
and appropriate sensitivity to GSH feedback inhibition (37;38).
Formation of GSH through GGT dependent pathways 
GSH contains a J-peptide linkage between glutamate and cysteine (Figure 1). 
The J-peptide bond promotes stability, as it is resistant to degradation by cellular 
peptidases. Plasma membrane bound GGT may, however, cleave the J-peptide bond 
of extracellular GSH, and thereby support intracellular synthesis of GSH (39). This 
NH
NH COOH
NH2
HOOC
O
SH
O
J-peptide linkage 
J-glutamyl glycinecysteinyl
Figure 1 Structure of GSH 
showing J-peptide linkage 
between amino acids 
glutamate and cysteine 
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cleavage of GSH is important since GSH can not be taken up by most cells, in 
contrast to the cysteine, which is formed by the action of GGT and a dipeptidase. 
GGT additionally facilitate the extracellular formation of J-GC (40). J-GC may then 
be taken up by cells where it can be further metabolized to GSH. These GGT 
dependent pathways may help maintain the GSH level in the short term when GSH is 
rapidly utilized, but they are not sufficient to restore GSH levels in the long term 
when de novo synthesis of GSH is needed. Upregulation of plasma membrane bound 
GGT is often seen in oxidative stress, and free plasma GGT is a useful biomarker for 
oxidative stress (41). 
Formation of GSH through glutathione reducatse 
The intracellular GSH level is also influenced by the flavoenzyme GR and the family 
of selenium dependent GPx. GPx catalyzes the oxidation of GSH with the 
concomitant reduction of hydro- and lipid-peroxides, thereby resulting in the 
formation of GSSG. GR reduces GSSG to GSH through a NADPH-dependent 
reaction (33).
GSH is in a constant state of turnover; its half life has been estimated as 5 hours in rat 
liver, 5 days in human erythrocytes and few minutes in human plasma (42-44).  
Numerous studies have demonstrated that GSH is an essential part of the antioxidant 
defence in all eukaryotic organisms. For example, experimental deletions of genes 
responsible for GSH synthesis in animals are lethal (especially in GCSh homozygous 
knock outs) and increases the vulnerability for oxidative stress, while overexpression 
of the same genes leads to enhanced defence against oxidative stress and extends life 
span (45-47). Furthermore, inborn genetic errors of such genes in humans are known 
to cause a wide spectra of GSH deficiency symptoms as reviewed by Townsend et al. 
and Ristoff et al. (30;48). 
Uric acid
Uric acid is produced from hypoxanthine and xanthine by xanthine oxidase (XO) and 
xanthine dehydrogenase (XDH) enzymes (49). In most species, urate oxidase 
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converts it further to allantoin and then gloxylate plus urea. Urate oxidase is absent in 
humans causing an accumulation of uric acid in plasma (49). The concentration of 
uric acid in human plasma is 0.05-0.9 mM (49). At physiological pH, it is present as 
urate ion since pKa of uric acid is around 5.4. Ames et al. (50) suggested that urate is 
a powerful scavenger of ROS in vitro, proposing that it functions as a biological 
antioxidant. Urate reacts with several reactive species like hydroxyl radical (OH•),
peroxyl radical (RO2•), singlet oxygen (1O2), hydrogen peroxide (H2O2), ozone (O3),
nitrogen dioxide radical (NO2•), peroxynitrite (ONOO-) and oxo-heme oxidants 
produced by peroxide reaction with haemoglobin (13;50). Urate binds metal ions like 
Cu and Fe making them poorly reactive in catalysing free-radical reactions (51;52). 
These reactions generates urate radical and the unpaired electron is localised over the 
purine ring, giving a resonance stabilized radical that does not react with oxygen to 
form peroxyl radical (RO2•) (13). The role of urate as an antioxidant is, however, 
controversial. Recently, large clinical studies have shown a high risk of cancer and 
cardiovascular mortality with high levels of serum uric acid (53-56).
Polypeptides –Thioredoxins, glutaredoxins and sulfiredoxins
Thioredoxins are polypeptides of relative molecular mass about 12000, found in 
both prokaryotes and eukaryotes (13). Three different variants of human Trx have 
been described: cytosolic Trx1, mitochondrial Trx2 and SpTrx which is highly 
expressed in spermatozoa (57). Both Trx1 and Trx2 are ubiquitously present in 
humans (58). Reduced thioredoxins contain two –SH groups in a conserved -Cys-
Gly-Pro-Cys- active site that form a disulphide in oxidized thioredoxin (57). Trx are 
involved in a variety of functions including reduction of ribonucleotide reductase and 
several transcription factors such as p53, nuclear factor-NB (NF-NB), activator 
protein-1 (AP-1), thereby playing a protective role against oxidative stress (57). They 
bind to target proteins and via intermediate formation of a mixed disulphide, reduce 
the protein disulphide bridge while oxidising themselves (13). Oxidized Trx are 
reduced in vivo in animals by TR. Glutaredoxins are thiol-disulphide 
oxidoreductases requiring GSH for their catalytical functions (15). Grx are present in 
most living organisms and catalyse the reduction of protein disulphide to their 
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respective sulphydryls by donating reducing equivalents to the oxidized proteins (15). 
The oxidized Grx gets reduced by GSH, which is oxidized to GSSG. Sulfiredoxins
are mainly present in eukaryotes and are involved in reduction of cysteine-sulphinic 
acid in the 2-cysteine Prx enzymes (59). They are also involved in 
deglutathionylation of proteins (60). 
Metal binding proteins 
Although metals like Cu, Zn and Fe are essential in almost all eukaryotes for the 
synthesis of various proteins involved in respiration, O2 transport and antioxidant 
defence. However, these metals also act as prooxidants and convert less reactive to 
more reactive species, for example Fe (II) and Cu (I) catalyses the formation of more 
reactive hydroxyl radicals (OH•) from less reactive hydrogen peroxide (H2O2) (13).
Various metal binding proteins are present in animal cells that bind metal ions 
thereby making them non-toxic. Metallothioneins are metal binding low molecular 
weight thiol proteins that are involved in the sequestration and distribution of metal 
ions especially Cu and Zn, removal of heavy metal ions from extracellular space (61). 
These proteins are rich in sulphur containing 22-33% cysteine thereby contributing 
significantly to total cellular protein thiol (13). The high –SH content also make them 
excellent scavengers of peroxynitrite (ONOO-), hypochlorous acid (HOCl), singlet 
oxygen (1O2) and hydroxyl radicals (OH•) (13). Other proteins like transferrin, ferritin 
and lactoferrin bind Fe (13). Caeruloplamin binds Cu and also exhibits ferroxidase 
activity; it oxidizes Fe (II) to Fe (III) and can facilitate iron loading on to transferrin 
and possibly ferritin (13). It also exhibits peroxidase activity in lung lining fluids 
(62). Fe can still act as prooxidant in some bound forms like haem and haem proteins. 
Plasma, however, contains haemoglobin-binding haptoglobins, as well as a haem-
binding protein (haemopexin). The binding of haemoglobin and haem to haptoglobin 
and haemopexin respectively, decreases their effectiveness in stimulating lipid 
peroxidation (13).
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Malfunctioning of the metal-binding proteins increases the concentrations of free 
metal ions making cells susceptible to oxidative damage as reviewed by Halliwell et 
al. (13). 
Albumin
Albumin is a small, highly soluble plasma protein at a concentration of about 40 
mg/ml (63). It contains an exposed –SH group at position 34 and contributes up to 
500 μM to total plasma thiols (13). Albumin has multiple roles including being an 
important extracellular antioxidant. Among its antioxidant roles, it binds Cu tightly 
and Fe weakly (13). It also binds haem thereby protecting lipoproteins against haem-
dependent oxidation (13). Albumin-SH reacts quickly with peroxynitrite (ONOO-),
nitrogen dioxide radical (NO2•), hypochlorous acid (HOCl), peroxyl (RO2•)- and 
alkoxyl (RO•)- radicals, and slowly with hydrogen peroxide (H2O2) (13). 
1.2.2 Dietary antioxidants 
Epidemiological studies show that a higher intake of fruits and vegetables decreases 
the risk of developing diseases like cardiovascular disease, stroke and certain types of 
cancer (64-68). The mechanisms behind this beneficial effect of fruits and vegetables 
are not fully understood. But we know that plants synthesize different 
phytochemicals that protect them against oxidative damage during photosynthesis 
and other abiotic stresses like drought, heat, cold and frost, effects of radiation levels, 
shade, altitude, soil nutrient and pollution (69). Since these phytochemicals are 
protective against oxidative damage, they are called as plant-antioxidants or dietary 
antioxidants. These antioxidants vary in their structure, physical and chemical 
properties and thus divided into various groups. Most commonly known groups are 
carotenoids, tocopherols, vitamin C and polyphenols.  
Plasma levels of some of these dietary antioxidants in humans are also inversely 
related to prevalence of some of these diseases and mortality (70-79). These diseases 
have oxidative damage and oxidative stress as underlying mechanisms in their 
pathogenesis. It was, thus, hypothesized that (a) these dietary antioxidants may play a 
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role in the prevention of human disease and (b) their mode of action is through their 
antioxidant properties, thereby reducing oxidative damage and development and 
progression of diseases.
The description of some of these dietary antioxidants and mode of their action both in
vitro and in vivo systems is described as follows: 
Carotenoids
Carotenoids are lipid soluble pigments (usually yellow, red or orange) that are 
widespread in plants. They are also present in some microorganisms and animals 
(snails, goldfish, salmon, bird plumage and lobsters) (13). Carotenoids belong to the 
tetraterpenes family, basic structure being a symmetrical tetraterpene skeleton 
containing eight isoprene units. Thus, all carotenoids possess a long conjugated chain 
of double bond and a near bilateral symmetry around the central bond (80). Different 
carotenoids are derived by modifications in the basic structure by hydrogenation, 
dehydrogenation, cyclization or oxidation (80). The class of carotenoids containing 
only carbon and hydrogen atoms are called as carotenes (E-carotene, D-carotene and 
lycopene) whereas xanthophylls carry at least one oxygen atom (lutein, zeaxanthin). 
Table 2 presents some of the major carotenoids. Due to the conjugate double bonds, 
carotenoids could exist as cis- or trans- geometric isomers. Trans-isomers are more 
common in nature presumably due to more stability of the long polyunsaturated chain 
in the linear, extended trans-form (80).
Fruits and vegetables constitute the major sources of carotenoids in human diet 
(Table 2). More than 600 different carotenoids have already been identified in nature. 
However, 40 carotenoids are present in a typical human diet and 20 carotenoids have 
been identified in human blood and tissues (81). Major dietary carotenoids include 
the hydrocarbons, E-carotene, D-carotene and lycopene and the xanthophylls, or 
oxygen-containing carotenoids, E-crytoxanthin, lutein and zeaxanthin. 
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Table 2 Structure and dietary sources of some major carotenoids 
Carotenoids Dietary sources 
Lutein
CH3
CH3 CH3
CH3
CH3CH3
CH3 CH3
CH3
CH3OH
OH
spinach, kale, broccoli, 
brussel sprouts 
Zeaxanthin 
CH3
CH3 CH3
CH3
CH3CH3
CH3 CH3
CH3
CH3OH
OH
egg yolks, maize, 
spinach
E-cryptoxanthin
CH3
CH3 CH3
CH3
CH3CH3
CH3 CH3
CH3
CH3OH
citrus fruits, avocado, 
papaya, pepper 
D-carotene
CH3
CH3 CH3
CH3
CH3CH3
CH3 CH3
CH3
CH3
Carrots, pumpkin, 
maize 
E-carotene
CH3
CH3 CH3
CH3
CH3CH3
CH3 CH3
CH3
CH3
Carrots, spinach, 
parsley
Lycopene
CH3
CH3CH3 CH3 CH3
CH3 CH3 CH3
CH3
CH3
Tomato and its 
products, water melon, 
guava
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The tissue and plasma levels of carotenoids vary with diet and bioavailability. The 
bioavailability depends upon how the food is processed and the type of food matrix in 
which carotenoids are located. Processing, such as mechanical homogenisation or 
heat treatment enhances the bioavailability (82). The ingestion of fat along with 
carotenoids also increases their intestinal absorption (82).
Carotenoids are transported by lipoproteins in human plasma. The distribution of 
carotenoids among lipoproteins is, however, dependent upon their physical 
properties: E-carotene, D-carotene and lycopene (hydrocarbons) tend to be localised 
predominantly in the low density lipoproteins (LDL), lutein and zeaxanthin 
(dihydroxy) are more localised in high density lipoprotein (HDL) whereas E-
cryptoxanthin (hydroxy) is equally distributed between LDL and HDL (83). 
Additionally, hydrocarbons (lipophilic) are located in the core of lipoproteins 
whereas xanthophylls (polar) are located on the surface.  Plasma carotenoids were 
measured in 3043 individuals from 16 different regions in Europe and a huge 
variation in plasma levels due to region of residence was observed (84). After region, 
BMI was the second most important predictor followed by smoking status, gender, 
season and alcohol intake for the variation in plasma levels of carotenoids (84).  
The antioxidant action of carotenoids in cell free experiments involves the ability of 
these pigments to physically quench or inactivate singlet oxygen (1O2). In doing so 
ground state oxygen and triplet state of carotenoid is generated. The triplet state of 
carotenoid returns to ground state by dissipating its energy through rotational and 
vibrational interactions with the solvent system (85). The efficacy of carotenoids for 
physical quenching depends upon the number of conjugated bonds that determines 
their lowest triplet energy state, presence of the functional groups in the molecule and 
the type of solvent used (86;87). Among different carotenoids, lycopene showed the 
highest quenching ability of singlet oxygen (1O2) (86). Carotenoids are also shown to 
react with other free radicals including chain-propagating  peroxyl radicals (RO2•)
which are generated in the process of lipid peroxidation (88). The reaction with free 
radicals is shown to act by three pathways: radical addition, electron transfer or 
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hydrogen abstraction depending upon the physical property of the carotenoids, type 
of reactive species and the environment (polar or non-polar) employed to study these 
reactions (87;88). 
The in vitro experiments have shown that added carotenoids prevent LDL oxidation, 
decrease DNA oxidation in lymphocytes (85). The in vivo studies done with animals 
have demonstrated an antioxidant action of carotenoid as reviewed by Krinsky et al 
(85). However, most experimental animals are very poor absorbers of carotenoids and 
only large pharmacological doses of carotenoids permit their absorption in these 
animals.
The best established role of carotenoids in humans is as a precursor of the fat-soluble 
vitamin A. About 50 carotenoids (not including lycopene) can generate vitamin A, 
the important ones being E-carotene, D-carotene and E-cryptoxanthin (89;90). 
Additionally, the recent report by World Cancer Research Fund (WCRF) (91) 
concluded that foods containing carotenoids probably protect against mouth, 
pharynx, larynx and lung cancer; while foods containing E-carotene and lycopene 
probably protect against oesophagus and prostate cancer respectively. The in vivo
protective action of supplemental E-carotene has been questioned (92).
Carotenoids can also act as prooxidants in cell models, but the prooxidant action is 
observed under certain circumstances namely high oxygen tension, high carotenoid 
concentration, unbalanced intracellular redox status (93). However, there is no 
evidence to support the hypothesis that dietary carotenoids may act as prooxidants 
within a biological system i.e. at physiological relevant partial pressure of oxygen.
Carotenoids also exhibit other non-antioxidant functions like immunomodulatory 
actions, induction of gap-junctional communication (GJC). During carcinogenesis, 
GJC is lost and this loss may be important for malignant transformation, and its 
restoration may reverse malignant processes (94). Carotenoids stimulate GJC in a 
differential and dose-dependent manner; however the underlying mechanisms are not 
yet understood (94). 
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Vitamin E 
Vitamin E was discovered by Evans and Bishop in 1922 and is a generic name for 
eight different isoforms with biological activity that have been isolated from plant 
sources: D-, E-, J- G- tocopherol and D-, E- J- and G- tocotrienol (Fig 1) (95). 
Tocopherols differ from tocotrienols only in their aliphatic chain. Tocopherols have a 
phytyl side chain attached to their chromanol nucleus, whereas the tail of tocotrienols 
is unsaturated and forms an isoprenoid chain (95). The various isoforms differ in their 
methyl substituents on the chromanol nucleus as shown in Figure 2. Each tocopherol 
has 3 asymmetric carbon atoms giving 8 optical isomers. Humans absorb all forms of 
vitamin E, but the body maintains only RRR-D-tocopherol, formerly called as d-D-
tocopherol (96). Dietary sources of Vitamin E are vegetable oils, nuts (especially 
almonds and hazelnuts), wheat-germ and grains (13). 
O
R1
OH
R2
CH3
CH3
CH3
CH3 CH3 CH3
O
R1
OH
R2
CH3
CH3
CH3
CH3 CH3 CH3
Figure 2 Different isomers of vitamin E- tocopherols (A) and tocotrienols (B) 
Vitamin E is a fat-soluble vitamin located in the lipophilic compartment of 
membranes and lipoproteins. This vitamin was discovered as a micronutrient that was 
essential for the reproduction in female rats. In humans, vitamin E deficiency 
R1 R2 Isomer 
CH3 CH3 D
CH3 H E
H CH3 J
H H G
A)
B)
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primarily causes neurologic dysfunctions, but the underlying molecular mechanisms 
are unclear (96). Vitamin E is also considered to be one of the most important lipid 
soluble antioxidants.
As an antioxidant, vitamin E is an important inhibitor of lipid peroxidation as it 
scavenges chain propagating lipid peroxyl radicals (RO2•) much faster than these 
radicals can react with adjacent fatty acid side chains or with membrane proteins. The 
rate constant of this reaction in vitro is 104 M-1s-1, three orders of magnitude higher 
than reaction of peroxyl radicals (RO2•) with lipids (50 M-1s-1) (97). The importance 
of this function is to maintain the integrity of long-chain polyunsaturated fatty acids 
in the membranes of cells and thus maintain their bioactivity (98). During its action 
as a chain breaking antioxidant, D-tocopherol forms a radical, which is resonance 
stabilized due to its chromanol nucleus. This radical is capable of reacting with 
another peroxyl radical (RO2•) to give non-radical products and thus one molecule of 
D-tocopherol is in principle capable of terminating two peroxidation chains (13). The 
tocopherol radical can also be reduced back to tocopherol through hydrophilic 
antioxidant ascorbic acid as shown by Constantinescu et al. (99) and Sharma et al. 
(100).
The non-antioxidant aspect of vitamin E is also studied which includes its 
antiatherosclerotic and anticarcinogenic properties through modulation of cell 
signalling, transcriptional regulation and induction of apoptosis. There is still no 
agreement if vitamin E acts through its antioxidative or non-antioxidative properties 
at physiological levels in humans as reviewed by Traber et al. (98) and Azzi et al. 
(101).
Finally, a review by Brigelius-Flohe et al. (96) analysing the vitamin E function and 
metabolism concludes that the functions of vitamin E are underestimated if only its 
antioxidant properties are considered and further research is required to study the 
essentiality of this vitamin for humans. 
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Ascorbic acid 
Ascorbic acid, also called as vitamin C was isolated by Szent-Györgyi in 1928. 
Ascorbic acid is a water soluble five-membered lactone containing two ionisable –
OH groups, with pKa1 and pKa2 as 4.25 and 11.8 respectively (Figure 2) (102). Its 
acidity (pKa1 = 4.25) exceeds of weak carboxylic acid such as acetic acid (pKa = 
4.75) due to the resonance stabilization of the monoanion form (102). Thus, at 
physiologic pH the monoanion ion form is favoured contributing more than 99% 
(102). Plants and some animals can synthesize ascorbate from glucose but humans, 
other primates, guinea pigs, some fish and fruit bats do not have the enzyme required 
for the terminal step (gulonolactone oxidase) and need ascorbate in the diet (13). 
Dietary sources of this vitamin include citrus fruits, guava, berries, mango, broccoli 
and peppers (13). 
O
OH OH
O
OH
OH
(A)
O
O O
O
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OH
(B)
Figure 3 Structures of ascorbic acid (A) and dehydroascorbic acid (B) 
 Deficiency of ascorbic acid causes scurvy with symptoms of spongy, bleeding gums 
leading to tooth loss, poor wound healing and swollen, weakened limbs (103). The 
molecular mechanisms of the antiscorbutic effect of ascorbic acid are largely, but not 
completely understood (103). It is a cofactor of at least eight enzymes involved in 
collagen biosynthesis. Collagen synthesized in the absence of ascorbate is 
insufficiently hydroxylated and does not form fibres properly, giving rise to poor 
wound healing and fragility of blood vessels (13). The current recommended dietary 
allowance (RDA) for ascorbic acid is 60 mg/day for healthy, non-smoking adult 
(103).
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Besides being an antiscorbutic, ascorbic acid is an excellent water-soluble reducing 
agent/antioxidant in biological fluids. It readily scavenges various ROS and RNS, 
such as superoxide anions (O2•–), hydroperoxyl radical (HO2•)  , peroxyl radical 
(RO2•), singlet oxygen (1O2), ozone (O3), peroxynitrite (ONOO-), nitrogen dioxide 
radical (NO2•) and hypochlorous acid (HOCl), thereby protecting lipids, proteins and 
DNA from oxidative damage (13). Ascorbic acid also regenerates lipophilic 
tocopherol from its radical, produced by scavenging of lipid-soluble radicals 
(99;100). The very low reduction potential of ascorbate and stability and low 
reactivity of the ascorbyl radical formed after scavenging reactive species makes it an 
ideal antioxidant and is also called as the “at the bottom of the pecking order” or 
“terminal water-soluble small molecule antioxidant” (104) . The ascorbyl radical 
either disproportionates to ascorbate and dehydroascorbic acid (DHAA) (Figure 3) or 
is reduced back to ascorbate by NADH-dependent semihydroascorbate reductase. 
DHAA is unstable at physiological pH, with a half life of about 6 min (105) and is 
rapidly and irreversibly hydrolysed to 2,3-diketogulonic acid and leads to the 
depletion of this vitamin. DHAA can, however be reduced back to ascorbate 
enzymatically by GSH-dependent DHAA reductase (106). Other proteins like 
glutaredoxin, thioredoxin reductase, protein dislulphide isomerase can also act as 
DHAA reductases (106;107).
Ascorbate can also act as a prooxidant in vitro. Being a powerful reducing agent, it 
reduces catalytic metal ions Fe (III) and Cu (II) to Fe (II) and Cu (I) respectively. 
These reduced metal ions are required in the Fenton reaction for the production of 
hydroxyl radicals (OH•). The prooxidant activity depends upon the concentration and 
form of metal ions, and a high concentration of free metal ions are required for this 
effect (102;108). The in vivo evidence for metal ion dependent prooxidant action is, 
however, sparse (108). Nevertheless, for patients suffering from iron-overload 
supplemental ascorbic acid could be detrimental and high doses are not recommended 
(109).
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As common for other dietary antioxidants like vitamin E and carotenoids, roles of 
ascorbic acid other than being an antioxidant are explored. Recent findings on the 
specific requirement of ascorbate for the activity of several 2-oxoacid-dependent 
dioxygenases involved in cell signalling and the activation of transcription factors 
opens new fascinating area for future research (109;110).
Polyphenols
Polyphenols represent a wide variety of compounds and are characterised by having 
more than two –OH groups. The different classes of polyphenols are hydroxybenzoic 
acids, hydroxycinnamic acids, anthocyanins, proanthocyanins, flavonols, flavones, 
flavanols, flavanones, isoflavones, stilbenes, and lignans (Table 3) (111-113). The 
total dietary intake is about 1 g/day and is much higher than other known 
antioxidants, about 10 times higher than ascorbic acid and 100 times higher than 
vitamin E and carotenoids (114). Bioavailability of polyphenols differs greatly; the 
absorption is accompanied by extensive conjugation and metabolism such that the 
forms appearing in the blood are usually different from the forms found in food as 
reviewed by Scalbert et al. (114) and Manach et al. (111). The plasma concentrations 
of total metabolites ranged from 0-4 μmol/L with an intake of 50 mg aglycone 
equivalents (111). 
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Table 3 Structures and dietary sources of different polyphenols. 
Polyphenols Examples Food sources 
Hydroxybenzoic acid  
R1
OH
R2
O
OH
Gallic acid Tea
Hydroxycinnamic acid
R1
OH
R2
O
OH
Caffeic acid 
Chlorogenic acid 
p-coumaric acid 
Coffee, white grapes 
Apples, cherries, pears 
White grapes, tomatoes, 
spinach
Anthocyanins
O
+
OH
R1
OH
R2
OH
OH
Cyanidin
Malvidin
Cherries, raspberry 
Strawberries,
blackberries, grapes 
Flavonols
O
OH
R2
R3
OH
OH O
R1
Quercetin
Myricetin
Kaempferol 
Onions, lettuce 
Cranberry, grapes 
Endive, leek, broccoli 
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Polyphenols Examples Food sources 
Flavanoles
O
OH
OH
R1
R3
OH
R2
Epicatechin
Gallocatechin
Green tea 
Apple, cocoa 
Flavones
O
OOH
OH
R2
R1
R3
Apigenin
Luteolin
Diosmetin 
Parsley
Celery
Sweet pepper 
Flavanones
O
OOH
OH
R2
R3
R1
Naringenin
Hesperedin
Citrus foods 
Prunes
Isoflavones
O
OR1
OH
OH
Genistin
Daidzein
Soybeans
Legumes 
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Polyphenols Examples Food sources 
Stilbenes
OH
H
H
OH
RO
Resveratrol Red grapes 
Lignans
CH2OH
OH
H3CO
CH2OH
OCH3
OH
secoisolariciresinol linseed 
In vitro, most polyphenols exert antioxidant effects, inhibiting lipid peroxidation by 
acting as chain-breaking peroxyl radical (RO2•) scavengers. In addition, phenols often 
scavenge other reactive species such as hydroxyl radicals (OH•), nitrogen dioxide 
radical (NO2•), dintrogen trioxide (N2O3), peroxynitrous acid (ONOOH) and 
hypochlorous acid (HOCl) (13). Some can react with superoxide anions (O2•–),
mostly the di- and polyphenols. The number of phenolic groups and their relative 
positions are key determinants of antioxidant activity as the phenolic groups can 
accept an electron to form relatively stable phenoxyl radicals. Some polyphenols with 
adjacent –OH groups can also act as metal chelators and can bind transition metal 
ions especially Fe and Cu often in forms poorly active in promoting free-radical 
reactions (13). This chelating ability of polyphenols can interfere with uptake of 
metals from the diet.
The in vitro effects of polyphenols on the DNA oxidation are both harmful and 
beneficial (115). Polyphenols can have harmful effects in the presence of transition 
metal ions such as Cu (II) and Fe (II). Polyphenols reduce these metal ions and the 
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reduced forms catalyze the formation of free radicals like hydroxyl (OH•) which 
cause DNA oxidation. Such breakage of DNA has been considered both beneficial 
(cytotoxic and apoptotic effects on tumor cells) and toxic (mutagenic effects on 
normal cells) (115).
Some, but not all, in vivo studies in animals (polyphenol compounds) and humans 
(polyphenol-rich foods or beverages) have demonstrated their protective effect 
against DNA damage and reduced susceptibility to LDL oxidation (115;116).
Besides being antioxidants, they also exert antithrombotic effects (115). 
Intervention with supplemental antioxidants 
Foods containing phytochemicals such as carotenoids, ascorbic acid, vitamin E and 
quercetin are protective against some cancers (91). However, the majority of studies 
find that antioxidant supplements (E-carotene, D-tocopherol and ascorbic acid) do not 
decrease the risk of oxidative stress related diseases and mortality. A meta-analysis 
by Bjelakovic et al. (117) and a recent report from WCRF (91) have shown that 
antioxidant supplements may increase total mortality and risk of developing lung 
cancer, respectively.
Possible explanations for these apparent conflicting results between dietary and 
supplemental antioxidants could be: The beneficial effect could be due to multiple 
antioxidants present together and working simultaneously in a network (as in fruits 
and vegetables) rather than single antioxidants. Thus, it is suggested that low doses of 
many antioxidants may contribute to a positive antioxidant defence network, while 
large doses of one or a few antioxidants as typically used in supplements may have 
prooxidant effects. For example in Supplemantation en Vitamines et Mineraux 
AntioXydants (SU.VI.MAX) study (118) and Antioxidant Supplementation in 
Atherosclerosis Prevention (ASAP) study (119), the intervention group received low 
doses of D-tocopherol, ascorbic acid , E-carotene and a protective effect against 
cancer and atherosclerosis was observed in men.  
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1.3 Assessment of antioxidant and oxidative stress 
biomarkers in clinical studies 
An imbalance between reactive species and defence system causes oxidative stress. 
The assessment of this oxidative stress can be approached by measuring reactive 
species produced either directly or the damage produced by them i.e., oxidative 
damage. The decrease in the antioxidant defence due to their utilization during 
oxidative stress is another approach for this assessment. 
1.3.1 Measuring reactive species 
The measurement of reactive species can be done by two approaches: 
x Trapping of these reactive species and measuring the trapped species by a 
technique called as electron spin resonance (ESR) or electron paramagnetic 
resonance (EPR).
x Measuring the oxidative damage done by reactive species, i.e., the amount of 
oxidative damage. 
Trapping of reactive species 
ESR is a spectroscopic technique that detects unpaired electrons and is thus specific 
for free radicals. The free radicals like superoxide anion (O2•–) and hydroxyl (OH•)
are, however, highly reactive with reaction time of microseconds to nanoseconds and 
this technique is not sensitive enough to detect them directly in living systems. These 
radicals are trapped by a trap molecule, forming more stable radicals that accumulate 
to a level permitting their detection by ESR (120). The ideal trap should react rapidly 
and specifically with the radical one wishes to detect, to produce a product that is 
chemically stable, not metabolized by living systems, and has a unique ESR spectrum 
(13). A wide range of traps are available for the use in animals and cell cultures 
(13;121). Examples of some of these trap molecules include D-phenyl-tert-
butylnitrone (PBN), 5,5-dimethyl-1-pyrroline N-oxide (DMPO).  
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Whole-body ESR techniques are being used on animals (122) but currently not on 
humans due to lack of human safety data for new probes. For humans, traps have 
been used ex vivo on body fluids and tissues like biopsies, blood and other tissue 
samples (120). Although the traps are added in ex vivo samples, it is impossible to 
detect free radicals like hydroxyl (OH•) with a reaction time of nanoseconds. ESR of 
ex vivo samples probably detects secondary radicals resulting from the reaction of 
these reactive species with biomolecules. Some of the examples are lipid derived 
radicals such as alkoxyl (RO•)- and peroxyl (RO2•)- radicals (120). Ascorbic acid also 
reacts with a large number of reactive species generating radical 
semidehydroascorbate radical (123). This radical can be detected by ESR and have 
been used as an indication of free radical production in organs, plasma and skin 
(100;124;125). Among the in vivo ESR in humans, aromatic free radical traps like 
salicylate and phenylalanine have been used to detect hydroxyl radicals (OH•) with
some success as reviewed by Halliwell et al. (120).
The potential limitations in the use of spin trapping technique are efficiency of radical 
trapping, selectivity and availability of spin traps, the limited stability of spin adducts, 
possible formation of artifactual spin adducts and under estimation due to removal of 
products giving ESR signal (126). For example, when DMPO is used to trap 
hydroxyl radicals (OH•), any ascorbate present can directly reduce the adduct between 
DMPO and hydroxyl radicals (DMPO-OH•) to an ESR-silent species. With the 
development of new and better spin traps going on, ESR can be a very effective and 
powerful technique in studying processes involving free radicals. 
Measuring oxidative damage 
An alternative to trapping is the method in which the reactive species are not 
measured themselves but the damage caused by them. When reactive species attack 
biomolecules, the oxidized products formed can be used as biomarkers to measure 
this damage. Most human studies focus on the measurement of oxidative damage 
rather than the total reactive species generated because of limited applicability to 
humans of the latter technique. Moreover, it is the damage that matters rather than the 
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total amount of free radicals generated. Criteria for a valid biomarker as described by 
Halliwell et al. (120) and Griffiths et al. (127) are: 
Fundamental criterion 
x The biomarker predicts the later development of disease. 
Technical criteria 
x The biomarker should detect a major part or at least a fixed percentage of total 
oxidative damage to the target molecule in vivo.
x It must employ validated measurement technology and is measurable within 
the limits of detection (LOD) of the method. 
x The coefficient of variation between different assays of the same sample 
should be very small in comparison with the differences between subjects or 
the effect of experimental manipulations (e.g. antioxidant supplementation) 
upon a subject. 
x It should be free of confounding factors from dietary intake. 
x It should ideally be stable on storage, not being lost, or formed artefactually, in 
stored samples. 
x For human use, it is preferable if it can be measured in easily obtainable 
samples, e.g. blood, urine, saliva, skin biopsy. 
Validation of biomarkers requires two steps. The fundamental validation showing 
that the changes in the biomarker reflect the development of the disease. The 
analytical validation includes development of methods, elimination of 
methodological artefacts, analysis of reference materials and quality control (13).
Markers of oxidative stress in vivo can be classified into three major groups: markers 
of oxidative damage to lipids, proteins and DNA. 
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Lipids
The lipid rich sites in vivo are the lipid-carrying lipoproteins and cellular membranes. 
Lipids can be oxidized, halogenated or nitrated by different reactive species apart 
from hydrogen peroxide (H2O2), nitric oxide (NO•) and  superoxide anion (O2•–) (13).
Lipid peroxidation is thought to proceed by radical mediated abstraction of a 
hydrogen atom from a methylene carbon on a polyunsaturated fatty acid (PUFA) or a 
PUFA side chain (128). It is a complex process and a wide range of products are 
formed in variable amounts (128). Lipid peroxidation plays a significant pathological 
role especially in atherosclerosis (8). The extent of lipid peroxidation can be 
determined by measuring the losses of PUFAs, the amounts of primary peroxidation 
products like hydroperoxides, conjugated-dienes, isoprostanes and the amounts of 
secondary products, such as hydrocarbon gases (13;127). 
Isoprostanes
The best available biomarker of lipid peroxidation appears to be the isoprostanes 
(IPs). They are prostaglandin-like compounds formed from PUFA with at least three 
double bonds such as linolenic acid and arachidonic acid (produce F2-IPs);
eicosapentaenoic acid (produce F3-IPs) and docosahexaenoic acid (produce F4-IPs).
Most of the work is done on F2-IPs and their metabolites. The most abundant F2-IP is 
8-isoprostagladin F2D (8-iso-PGF2D). They are measured by gas chromatography-mass 
spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) or 
immunoassays, the latter being less reliable. GC-MS techniques are quite established 
but the sample preparation techniques are quite tedious (129). LC-MS techniques do 
not require derivatization step and are less prone to artifacts (129). F2-IPs can be 
measured in plasma, urine and other body fluids with urine generally considered as a 
better matrix due to following reasons. The correct storage of plasma and tissues 
samples is important as artefactual lipid oxidation and IP formation can occur unless 
antioxidants like butylated hydroxytoluene (BHT) are added (13). In plasma and 
tissues most IPs are esterified with phospholipids and it is important to identify 
between free and total IPs (13). Another disadvantage in plasma is that it is not 
possible to measure them over a period of time due to their short half-life 
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(approximately 18 minutes) in plasma (127). These challenges can be overcome by 
measuring IPs in urine. However, local kidney peroxidation could be a problem for 
urinary F2-IP measurement. This can be overcome by measuring both 8-iso-PGF2D
and its metabolite 2,3-dinor-5,6-dihydro-8-iso-PGF2D in urine (13;130). Other factors 
like fasted samples can increase the F2-IPs levels in urine and thus these samples are 
to be regarded with caution (13). Additionally, 24-hour urine sample collection and 
standardization of F2-IPs concentrations with creatinine are suggested (9).
Increased levels of IPs in plasma / urine are observed in animals and humans 
associated with oxidative stress, including renal, cardiovascular, lung, 
neurodegenerative diseases, diabetes, hypertension (120;131) . Modulation of IPs by 
antioxidant supplementation is also reported (127;132-134). Different PUFAs 
generate different IPs, giving a possibility to follow the peroxidation of individual 
PUFAs in vivo.
Aldehydes
Many aldehydes and carbonyls are generated during lipid peroxidation, including 
malondialdehyde (MDA) and 4-hydroxynonenal. The concentrations of free 
aldehydes in vivo are probably low, because they are readily conjugated to proteins. 
Spectrophotometric, chromatographic and antibodies based methods are used 
(13;127). The most commonly measured aldehyde in plasma or urine is MDA, 
usually measured by thiobarbituric acid (TBA) test. MDA is heated with TBA under 
acidic conditions, forming an adduct which is detected spectrophotometrically at 532 
nm (127). The test is highly unspecific as many others compounds not related to lipid 
peroxidation reacts with TBA forming the similar chromogen (13;127). Measuring 
the fluorescence of MDA-TBA adduct instead will improve the specificity. However, 
the assay becomes even more specific by performing a chromatographic separation of 
MDA-TBA from interfering chromogens (127). Use of MDA as a biomarker for lipid 
peroxidation has a number of limitations as reviewed elsewhere (13;127). One of the 
important limitation include that the formation of MDA could be due to other 
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processes and not always due to lipid peroxidation. The test is, however, still widely 
used due to the low cost and easy to perform  
Peroxides
Lipid peroxidation also generates different peroxides and a number of different 
assays measuring total and individual peroxides are available (13). Some of the 
assays available are iodine liberation, ferrous oxidation xylenol orange (FOX), 
cyclooxygenase (COX), derivatives of reactive oxygen species (d-ROMs). d-ROMs 
are the indirect way of measuring hydroperoxides in plasma/serum. The 
hydroperoxides are decomposed in presence of metal ions forming RO• and RO2•
radicals. These radicals oxidize the chromgen N,N,-diethylparaphenylendiamine, 
thereby changing its colour from pink to red, which is measured spectrophometrically 
(135). The hydroperoxides in biological samples also arise from the attack of reactive 
species on other organic molecules. Thus, d-ROMs are not a specific biomarker of 
lipid peroxidation but a more general biomarker for oxidative stress. Hayashi et al. 
(136)  have measured d-ROMs in serum of smokers and non-smokers and found that 
the smokers have higher levels of plasma d-ROMs. 
Conjugated dienes
The oxidation of PUFAs form conjugated dienes that absorb ultraviolet (UV) light in 
the 230-235 nm wavelength range (13). Measurement of dienes is useful in pure 
lipids detecting an early stage lipid peroxidation. However, an application of this 
technique to human body fluids or their extracts results in an overestimation due to 
presence of other substances that also absorb strongly in the same UV range. 
Although extraction of lipids before their measurement could solve this problem, the 
dienes can also arise from other sources besides lipid peroxidation such as diet or 
microbial metabolism in the gut (13). Thus, the validity of this biomarker for lipid 
peroxidation is questionable. 
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Breath analysis 
Exhaled air contains F2-IPs, aldehydes and a range of hydrocarbons including ethane 
and pentane (120). Ethane is derived from n-3 PUFAs and pentane from n-6 PUFAs. 
Both gases can be measured by GC. The expired gas is passed through an absorbent 
at low temperatures to bind and concentrate the hydrocarbons, which are desorbed 
and measured (13). Hydrocarbons are however minor end products of peroxidation 
and their formation are affected by the transition metal ions to decompose peroxides, 
O2 concentrations and altered liver metabolism (13;127). Other disadvantages of this 
biomarker are that other sources including presence of bacteria and environmental 
factors like air contamination due to motor vehicles can contribute to hydrocarbons 
(13;127). Contamination of pentane due to the presence of another hydrocarbon 
isoprene can give erroneous results (13;127). This can be solved by measuring ethane 
instead of pentane. Exhaled hydrocarbons are also difficult to measure routinely in 
large human studies, requiring cumbersome equipments.  Increased exhalation with 
age, hyperoxia, smoking, scleroderma and some lung diseases has been demonstrated 
in some human studies (9;13). 
DNA
Oxidative DNA damage seems to relate to an increased risk of cancer development 
with age. At molecular level, DNA damage can take many forms, ranging from 
specifically oxidized purine and pyrimidine bases (more than 20 such oxidative 
lesions have been identified) to gross DNA changes such as strand breaks, sister 
chromatid exchange and the formation of micronuclei (137;138). The DNA oxidation 
products formed depend upon the type of reactive species involved, its rate of 
production and the ability of the cell to repair the damage (137). The oxidative DNA 
damage can be measured as steady state damage in accessible cells like leukocytes, 
colonic endothelium and buccal cells (137). The steady state damage reflects the 
balance between damage and repair, and an increase in oxidative DNA damage could 
be due to increased damage and/or decreased repair. Another approach is to measure 
the total in vivo oxidative DNA damage by measuring products of DNA repair that 
are excreted in urine (13).
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Oxidized nucleosides/bases
Among the most commonly measured biomarkers of total oxidative DNA damage is 
the modified nucleoside 8-oxo-7,8-dihydro-2´-deoxyguanosine (8-oxo-dGuo) or base 
8-oxo-7,8-dihydroguanine (8-oxo-dGua) , considered to be a biologically important 
lesion. The mutagenic and carcinogenic potential of any modified DNA base is 
reflected in its miscoding properties. The presence of 8-oxo-dGuo residues in DNA 
can lead to GC to TA transversion, and if not repaired can lead to mutagenesis and 
may be carcinogensis (127). Other less studied oxidized bases like 2-hydroxy-
adenine, 8-hydroxy-adenine and 5-OH-Cyt have also shown to be mutagenic (127).  
The techniques for the measurement of 8-oxo-dGuo in cells and urine are usually 
chromatographic employing liquid chromatography-electrochemical detection (LC-
ED) or GC-MS or liquid chromatography-tandem mass spectrometry (LC-MS-MS), 
comet assay and immunoassay (127;139). The results from different techniques vary 
over a range of three orders of magnitude in cells and the European standards 
Committee on Oxidative DNA Damage (ESCODD, 1997) has been testing ability of 
different laboratories using different method to measure 8-oxo-dGuo in standard 
samples, calf thymus DNA, pig liver, oligonucleotides, HeLa cells and in 
lymphocytes isolated from blood of volunteers (139).  
Chromatographic 
The chromatographic based techniques measure 8-oxo-dGuo in both cells and urine. 
In cells, LC-ED is capable of measuring 8-oxo-dGuo with high accuracy but there is 
a lack of consensus on basal levels measured (127;139). Advantages with GC-MS are 
that many different modified purines and pyrimidines can be detected but GC-MS 
failed to detect a dose response of induced 8-oxo-dGuo and cannot reliably measure 
low levels of damage (127;139). New techniques like LC-MS-MS, although quite 
specific has yet not proved capable of measuring low levels of oxidative DNA 
damage. The limitations with chromatographic methods include artefactual oxidation 
during sample preparation, low limits of detection and lack of specificity (especially 
in HPLC-ED) (127). The artefactual oxidation can be avoided by use of antioxidants, 
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eliminating traces of oxygen, room temperature derivatisation, and use of repair 
endonucleases to liberate base products instead of acid hydrolysis (127). It is also 
important to accurately measure unoxidized base (dGuo) as the concentration of 8-
oxo DGuo is expressed relative to dGuo.
Besides measuring in cells, urinary 8-oxo-dGua and 8-oxo-dGuo can be used to 
assess oxidative DNA damage. It is assumed that the products of oxidative DNA 
damage are excreted in urine and represents the primary product of repair in vivo. The 
advantage of analysing in urine is that the levels of 8-oxo-dGuo and 8-oxo-dGua do 
not depend upon the diet in humans and are not susceptible to oxidation (127). GC 
with isotope dilution MS and LC-MS-MS are the techniques that are currently being 
used for their analysis (140). The limitation of this biomarker  is its specificity i.e., 
processes other than repair processes can also contribute to 8-oxo-dGua and 8-oxo-
dGuo levels in urine (127).
Comet assay 
An alternative approach to measure DNA damage in cells is by comet assay. This 
technique can be applied to any type of cells provided they have been isolated from 
tissue without degradation (127). In human studies, lymphocytes are used as 
surrogate tissues. Comet assay is a simple, fast and sensitive technique that measures 
both DNA strand breaks and oxidized bases (127). The DNA strand breaks are 
measured by subjecting the isolated nucleoids from lysed cells to alkaline 
electrophoresis. The negatively charged DNA are attracted to the anode but only the 
loops of DNA possessing a break are free to migrate, presenting the image of a comet 
with a tail (127) called as comet images. The quantitation of these images is done by 
computer image analysis or a visual scoring system (class 0 no tail, class 4 all DNA 
in the tail). The calibration is achieved against X-ray irradiated cells, where the 
frequency of strand breaks introduced is known. The measurement of oxidized bases, 
however, requires an additional step of DNA incubation with bacterial repair 
endonucleases. The endonucleases recognise and remove damaged bases and make 
nicks at the resulting abasic sites in the DNA (127). Endonuclease III detects 
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oxidized pyrimidines and formamidopyrimidine DNA glycosylase (FPG) recognises 
altered purines including 8-oxo-dGuo (127). These repair enzymes (endonuclease III 
or FPG) are added to isolated nucleiods and parallel gels (with and without enzymes) 
are run. The comet scores are subtracted, calculating the degree of oxidative damage.  
Advantage of this assay as compared to chromatographic techniques is that there is 
little chance for artefactual oxidation. The potential problems with assay can be 
calibration, linearity, lesions occurring in close proximity with in one DNA loop will 
be registered as one lesion leading to underestimation or unspecificity of FPG leading 
to overestimation (127). 
Immunoassay 
The enzyme-linked immunoabsorbent assays (ELISA) have also been used to assess 
8-oxo-dGuo.  Both polyclonal and monoclonal antibodies are commercially available 
(140). These assays are much simpler, more reproducible, robust and versatile in 
comparison to chromatographic methods. The baseline values in healthy individuals 
are also consistent between different laboratories (120;127). Since DNA extraction 
and hydrolysis are required prior to ELISA, the artefactual oxidation should be 
avoided. On comparing chromatographic methods and ELISA a poor correlation is 
observed, additionally the latter giving two to four times higher values than the 
former (127;140). The main reason is the cross-reactivity of antibodies employed in 
ELISA towards other species in urine (127;140).
Proteins
Oxidative protein damage is studied to lesser extent as compared to lipid peroxidation 
and DNA oxidation. It could be due to the complexity since 20 different amino acids 
can be attacked by reactive species forming different oxidative products (127). Free 
radical attack on proteins can generate amino-acid radicals, which may crosslink or 
react with O2 to give peroxyl radicals (RO2•) resulting in a variety of reactive species 
(120). Of the 20 amino acids, aromatic and sulphydryl containing residues have 
considered to be most susceptible to oxidation. Markers of protein oxidation include 
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protein carbonyls derivatives, oxidized amino acid side chains, protein fragments, and 
formation of advanced glycation end products (AGEs) (137). 
Protein carbonyls 
Protein carbonyls are formed by the oxidative cleavage of the peptide main chain or 
by oxidation of the following amino acid side chains: arginine, lysine, praline and 
threonine (137). Additionally some lipid peroxidation products including HNE and 
MDA can form adduct with amino acids generating carbonyls (137). The techniques 
employed to measure carbonyls are immunodetection by ELISA, western blot and 
chromatographic (127). Proteins carbonyls are first derivatized by 2,4-dinitro 
hydrazine (2,4-DNPH) to yield the corresponding 2,4-dinitrophenyl hydrazones 
(127). Hydrazones can be separated by HPLC and detected by UV or 
immunochemically by commercially available antibodies.  
Protein carbonyls are a generic and not specific marker of protein oxidation. Since 
carbonyls are usually formed by oxidative mechanisms, and this assessment of 
protein modification can provide a reasonable index of oxidative stress index. Protein 
carbonyls have been most strongly linked with aging and in Alzheimer diseases 
(137).
Other biomarkers from the amino acid oxidation products include kynurenines (from 
tryptophan), bityrosines, valine and leucine hydroxides, L-dihydroxyphenylalanine (l-
DOPA), ortho-tyrosine, 3-nitro tyrosine (attack of ONOO- upon proteins) (127). 
Although studied to lesser extent, the oxidative damage to proteins could be 
important as the changes in the proteins can alter the function of receptors, enzymes 
and can cause secondary damage to other biomolecules like inactivation of DNA 
repair enzymes (120).
Oxidative stress biomarkers- conclusion    
Oxidative biomarkers for measuring oxidative damage are in the establishing phase 
and the results are showing that some are better than others. The final conclusions 
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about biomarkers of lipids, proteins and DNA oxidation) are taken from the ESSCOD 
recommendation (127) that are as follows: 
x For lipid oxidation biomarkers, determination of lipid peroxides and IPs is 
considered suitable with further work necessary on urinary IP metabolites and 
hydrocarbon gases. Measurement of TBARS, MDA and conjugated dienes is 
considered inappropriate. 
x For DNA oxidation biomarker, measuring 8-oxoGua in DNA is suitable, but 
further work is required on other oxidized base analysis, enzyme sites in the 
comet assay and 8-oxo-dGuo measurement in urine by chromatography or 
ELISA. Strand break analysis alone is inappropriate. 
x Protein oxidation biomarkers are in earlier stages of validation. The suitable 
candidates, however, include nitrated amino acids, protein-bound tyrosine 
oxidation products, protein-bound tryptophan products, and methionine 
sulphoxide.
1.3.2 Decrement in antioxidant defence 
Another approach is to measure the decrement in the antioxidant defence as increased 
production of free radicals will result in the more utilisation of various endogenous- 
and dietary- antioxidants. Some of these are described below. 
Glutathione
It is well accepted that cellular concentrations of GSH and its oxidized form-GSSG 
are related to oxidative stress, and that the level of GSH and GSSG reflect the degree 
of oxidative stress in different pathophysiological conditions (25;30;141).
Measurements of total GSH, free GSH and GSSG have been used extensively to 
estimate oxidative stress or the redox environment of cells. Many researchers have 
estimated oxidative stress by using the ratio [GSH]/[GSSG]. This is convenient for 
many measurements since the absolute concentrations are not needed. Recently, the 
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redox state of the GSSG/2GSH couple calculated with the Nernst equation was 
suggested to describe the redox environment of biological fluids, cell organelles, 
cells, or tissue (141). Redox state is considered to be better parameter as compared to 
the ratio since it takes into account the correct stiochiometry involving GSH and 
GSSG, which is a two-electron process. The redox (reduction) potential of this couple 
calculated by Nernst equation given by: 
Ehc = -240 - (59.1/2) log ([GSH]2/[GSSG]) mV 
There are many redox couples in a cell that work together to maintain the redox 
environment, but Schafer and Buettner (141) suggest that the redox state of the 
GSSG/2GSH couple can serve as an important indicator of redox environment since 
it is the most abundant redox couple in the cell. Additionally, decrease in GSH redox 
potential has been observed with aging, smoking, and diabetes (142;143)..   
GSH can be measured in whole blood, erythrocyte, plasma, leukocytes, platelets and 
various tissues. The total concentration of GSH in whole blood and serum/plasma is 
about 2 mM and 5 PM, respectively. Erythrocytes constitute 40-50% of the blood 
volume and contribute about 99 % of GSH in whole blood. Whole blood analysis of 
GSH therefore almost exclusively reflects erythrocyte GSH.
The ratio of GSH and oxidized forms of GSH is different in erythrocytes as compared 
to plasma (144;145). In erythrocytes, the major form of GSH is the reduced free form 
of GSH, which accounts for about 76 % of the total GSH. GSSG represents 8 % and 
PSSG accounts for about 16 % (145). In plasma, the reduced free from of GSH 
represents about 62 % of the total, whereas GSSG and mixed disulfides represent 18 
% and protein-bound represents about 20 % (144). Thus, the redox state of GSH is 
more oxidized in plasma as compared to the erythrocytes (146).  
Both chromatographic and enzymatic methods are available for the measurement of 
GSH and GSSG (147;148). The reported concentrations of total GSH (sum of free 
GSSG + 2H+ + 2e- 2GS
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GSH, GSSG, mixed GSH disulphides and protein bound GSH), free GSH and GSSG 
in blood, erythrocytes, leukocytes, platelets and plasma vary considerably. The 
reasons for this variation are as follows: 
x GSH can be easily oxidized during sample preparation 
x  GGT which is found in plasma and most cells can degrade GSH if the 
enzyme is not inhibited during sample preparation 
x  Plasma values are easily increased by incidental and non-reproducible 
leakage from erythrocytes having 1000-times higher GSH and GSSG 
concentration than plasma. 
The challenges for the determination of GSH and GSSG in blood and erythrocytes 
have been discussed elsewhere (149-152). The precautions for the determination of 
GSH and GSSG in plasma are discussed by Jones et al. and Sakhi et al. (153;154).
A major conclusion of these articles is that it is essential to inhibit GGT mediated 
degradation of GSH by either serine borate or acivine, and to stop artificial oxidation 
of GSH by blocking the thiol group of GSH before the precipitation of proteins with 
an acid.
A number of different sample preparation and analytical methods are available, and a 
variety of GSH forms may be measured. The nomenclature that has been used to 
describe these different forms of GSH is inconsistent. For example, total GSH may in 
some texts refer to the sum of free reduced GSH and GSSG, while in other texts it 
reflects the sum of all forms of GSH (i.e. also including PSSG and GSH bound to 
other small molecular weight thiols). Thus, it is important to define which GSH form 
is being measured. 
Total antioxidant capacity 
Antioxidants form an intricate network in the protection against reactive species and 
analysing only one antioxidant may give an in complete overview. This provides the 
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rationale for analysing all the antioxidants present in the sample by measuring total 
antioxidant capacity (TAC). TAC is usually measured in plasma /serum. The main 
determinants of the plasma /serum TAC are urate (60%), ascorbate and protein thiols 
(155).
Several different assays are available to measure TAC. Assays involving oxidants 
that are not necessarily pro-oxidants are ferric ion reducing antioxidant power 
(FRAP), Trolox equivalence antioxidant capacity (TEAC) and cyclic voltammetry 
whereas assays involving oxidants that are necessarily pro-oxidants are total radical 
trapping antioxidant parameter (TRAP), oxygen radical absorbance capacity (ORAC) 
(156).
Anticoagulant and storage of samples are critical factors that affect the TAC. This is 
due to ascorbate, which is among the major contributors to TAC and decays rapidly 
on storage. The use of TAC as an indicator of the antioxidant defence has been 
contradicting due to its increases under the enhanced oxidative stress conditions 
(127). This is mainly due to high contribution of uric acid in plasma, obscuring the 
changes in the concentrations of other antioxidants and thus limiting its usefulness. 
Measurement of dietary antioxidants- carotenoids, vitamin E and 
ascorbic acid 
Plasma levels of various carotenoids, vitamin E and ascorbic acid are decreased in 
smokers and various oxidative stress related diseases as compared to healthy controls, 
and thus can be used as biomarkers for oxidative stress. However, their plasma/serum 
levels are affected by diet, and thus it is important to have a control over changes in 
dietary patterns during the measurement period.  
Carotenoids
Carotenoids are usually measured in plasma/serum. HPLC with ultraviolet (UV) 
detection is the most common method employed for their determination (157). 
Carotenoids are highly lipophilic and require organic solvents like isopropanol, 
hexane for their extraction from the plasma samples.Carotenoids are light sensitive 
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and must be protected during sample preparation. The type of anticoagulant used in 
blood sampling tubes also effect the concentration of carotenoids. The plasma 
concentration of total carotenoids is approximately 1-3 μmol/L (84). 
Non-invasive method for measuring carotenoids in skin and eye using Raman 
spectroscopy are also developed (158). The method is shown to be precise, specific, 
sensitive and well suitable for clinical as well as field studies (159). The only 
disadvantage with this method is that only total, and not individual, carotenoid 
concentration can be measured.
Vitamin E 
Vitamin E isomers are usually measured in plasma/serum. Vitamin E exhibit native 
fluorescence and thus HPLC with fluorescence detection is the commonly employed 
technique for their determination. For biological samples, reversed phase 
chromatography is employed and the separation of all the vitamin E isomers is 
achieved by only some (160;161) but not all columns. Protection from light and type 
of anticoagulant in blood sampling tubes should be considered during sample 
preparation. EDTA plasma is considered to be most suitable for their determination 
(162). The concentration in plasma is 15-40 μmol/L: Being lipid soluble, it is more 
accurate to express vitamin E concentration as the molar ratio of vitamin 
E/cholesterol (163). 
Ascorbic acid 
Ascorbic acid is oxidized to DHAA and the ratio of DHAA/total ascorbic acid can be 
used as a biomarker for oxidative stress. Ascorbic acid and DHAA are usually 
measured in plasma, using HPLC with UV detection. Ascorbic acid can be easily 
oxidized at neutral or alkaline pH and thus acidification of plasma should be done 
immediately (164). The type of anticoagulant also effects its concentration and 
heparin plasma is most suitable for its determination (164). The concentration of 
ascorbic acid in plasma is approximately 30-80 μmol/L. 
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1.4 Cancer and oxidative stress 
It is evident that elevated levels of ROS/RNS can lead to cancer (10). The specific 
mechanism by which oxidative stress contributes to the development of 
carcinogenesis is not fully understood. The most common explanation, however, is 
the DNA oxidative damage by ROS/RNS. Cancer development is a micro-
evolutionary and multistage process and requires the cumulative action of multiple 
events that occur in one cell alone (165). These events include a three stage model: a 
permanent change in one somatic cell genetic material (initiation); the expansion of 
the mutated cell alone (promotion); and the malignant conversion into cancer 
(progression) (165). ROS/RNS can stimulate carcinogenesis by acting at all three 
stages.
Initiation
Initiation involves a non-lethal mutation in DNA producing an altered cell. Oxidative 
DNA damage occurs through the attack of ROS/RNS especially OH• (10). The yield 
of the individual DNA modifications is highly dependent on which reactive species 
are involved (166). Thus, 1O2 induces prefentially 8-oxodGuo whereas OH• attack 
upon DNA generates a whole series of DNA damage by a variety of mechanisms 
(165;166). These include sugar and base modifications, strand breaks and DNA-
protein cross-links. Modified DNA bases (pyrimidine and purine) are one of the most 
common lesions and 8-oxodGuo represents one of the most studied lesions due to its 
mutagenic properties. Some RNS deaminate DNA bases to mutagenic lesions such as 
ONOO- forms 8-nitroguanine (8-NG) in DNA. 8-NG rapidly detaches from the DNA, 
leaving potentially mutagenic apurinic sites (10). The damage caused by ROS/RNS 
can still be repaired by interrupting temporarily their cell cycle stage G1, S or G2 
(check points), repairing the damage, and resume division (167). However, a very 
small part of the oxidative DNA lesions escape repair and represents an important 
mutagenic potential that accumulates with age (168). Higher doses of ROS/RNS 
increase the chance that the DNA lesions may not be effectively encountered by 
DNA repair. Thus, exposure of mammalian cells to various reactive species increases 
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mutagenesis. The contribution of reactive species to carcinogenesis becomes even 
more important if DNA base changes occur in certain oncogenes and tumour 
suppressor genes.
Promotion
The promotion stage is characterised by the clonal expansion of mutated cells by the 
induction of cell proliferation and /or inhibition of programmed cell death (apoptosis) 
(167). This stage is still reversible and the cells proceeding towards progression 
requires optimal production of ROS and continuous presence of tumour promotion 
stimulus (167). A high level of oxidative stress is cytotoxic to the cell and halts 
proliferation by inducing apoptosis. A low level of oxidative stress can in fact 
stimulate the cell division in the promotion stage and thus stimulate the promotion of 
tumour growth (167).  
Progression
Progression is the third and irreversible stage of the carcinogenesis process, leading 
to the transition of the cell from benign to malignant (167). This stage involves 
accelerated cell growth, tissue invasion, increased genetic instability and metastasis 
(165).
ROS can increase proliferation in tumour cells by decreasing gap juctional 
communication (GJC), thus, corrupting the contact growth inhibition signals (10). 
ROS is also involved in another important step in tumour progression, angiogenesis. 
Angiogenesis generates new blood supplies that feed the malignant cells as required 
for the growth of any tumour (167). The ROS involvement include generation of 
reactive oxygen intermediates by cancer cells, damage to vascular basement 
membranes mediated by endothelial injury or perturbation, and direct activation of 
latent matrix metalloproteinases (165). The experimental tumours have also increased 
levels of inducible nitric oxide synthase (iNOS) and the nitric oxide (NO•) released 
increase vascular permeability enhancing tumour progression and angiogenesis (165). 
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1.5 Oxidative stress and head and neck squamous cell 
carcinoma
The head and neck cancer include cancers of the oral cavity (lip, the base of tongue, 
gum, floor of mouth and palate) pharynx (oropharynx, hypopharynx and 
nasopharynx) and larynx (Figure 4) (169).
Ninety percent of these cancers are squamous cell carcinomas (91). Worldwide, head 
and neck cancers are the seventh most common cancers (91), with approximately 
540 000 new cases annually and 271 000 deaths (170). In Norway 400-500 new cases 
are registered each year (171). Despite advances in treatment, five-year survival rates 
has improved marginally and are around 50-60 % over the past 20 years (91). While 
the primary cancers have been successfully treated, the development of second 
primary tumours (SPT), relatively high median age of 50 years or more and co-
morbidities are the important factors determining survival in these patients (91;172). 
The incidence of this cancer is about three times more in men as compared to women 
and more in African-American people than in white people (91;173). HNSCC has 
strong link to oxidative damage as major risk factors include tobacco use and alcohol 
consumption in developed countries and betel quid chewing and bidi smoking in 
many developing countries (91;174;175). Other factors include dietary habits, 
papillomavirus infection and polymorphisms of GSH S-transferase (91;174;176-178). 
Figure 4 Different regions of head and neck 
cancer. The figure is taken with permission from 
the following site: 
http://training.seer.cancer.gov/ss_module06_head_n
eck/unit02_sec02_anatomy.html 
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The geographic area with the highest incidence from oral and pharyngeal cancers are 
south-central Asia, Europe, Oceania and southern Africa, while for laryngeal cancer 
are South America, south-central and western Asia, and southern, central and western 
Europe (91).
1.5.1 Smoking and alcohol 
Smoking and alcohol are the established risk factors and contributes to about 90 % in 
the development of HNSCC cancer (91). While smoking rates are declining in the 
developed world, they are increasing in the developing world. Striking variations in 
head and neck cancer sites and incidence seen among different regions, cultures, and 
demographic groups are due in large part to differentiating patterns of tobacco and 
alcohol abuse (174;179). Alcohol is an important independent promoter of 
carcinogenesis and is a contributive factor in at least 75 % of HNSCC cases (173). 
Alcohol appears to have an effect on risk of HNSCC independent of tobacco 
smoking, but these effects are consistently significant only at the highest level of 
alcohol consumption (173). It also appears that alcohol consumption potentiates the 
carcinogenic effect of tobacco at every level of tobacco use (173).
Smoking and oxidative stress 
Cigarette smoke contains approximately 1017 oxidant molecules per puff (180). The 
free radicals in cigarette smoke are produced (a) during the burning of tobacco and 
the smoking process and (b) generated when the gas phase and the constituents from 
the particulate matter are oxidized in the smoke aerosol or dissolved in oxygenated 
aqueous solutions or biological media (181). Analysis of both particulate phase, gas-
phase in cigarette smoke have detected different oxidants like superoxide anion (O2•–
), quinones, hydrogen peroxide (H2O2), redox active metals (iron and copper), other 
heavy metals (cadmium, lead, mercury and arsenic), nitric oxide (NO•) and different 
nitroso carbon-centered radicals (181).
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Most of these species are highly reactive and increase oxidative damage in smokers. 
Free radicals from cigarette smoke have shown to cause peroxidation of the PUFA in 
cell membranes (182).  Isoprostanes are increased in exhaled air, plasma and urine in 
several studies (180;182). A dose-response relationship was observed between the 
number of cigarettes and urinary 8-iso-PGF2D(180). Increased levels of MDA have 
been found associated with current smoking status in population based studies (180). 
Biomarkers for protein oxidation, 3-nitrotyrosine is elevated in plasma and platelets 
of chronic smokers (183;184). The acute effects of smoking (an effect measured 
during the 24 hours after smoke exposure) increases markers of oxidative stress in 
humans, animals and in-vitro models as reviewed by van der Vaart et al. (182) The 
exposure to oxidant chemicals in smoke are also associated with depletion of 
endogenous levels of antioxidants. Cigarette smoking decreases plasma total 
antioxidant capacity, serum levels of ascorbic acid, D-tocopherol, different 
carotenoids (D-carotene, E-carotene, E-cryptoxanthin, lutein/zeaxanthin)
(180;185;186). Diet also influences the levels of these antioxidants. After correcting 
for dietary intake, plasma ascorbic acid and E-carotene still showed an inverse 
relationship with cigarette consumption (180;186). Plasma levels of GSH and 
cysteine decreased in smokers as compared to non-smokers (187). Serum selenium 
and erythrocyte GPx activities were also lower in smokers (185). 
Thus, smoking increases oxidative damage and stress in biological systems. 
Alcohol and oxidative stress
The toxicity of alcohol abuse is mediated through high intake of ethanol. The 
metabolic pathways of ethanol could produce free radicals that affect the antioxidant 
system (188). Ethanol ingestion causes an increase in free radical generation in the 
liver by induction of microsomal cytochrome p-450, conversion of xanthine 
dehydrogenase into xanthine oxidase in cytosol and increases one electron reduction 
in mitichondria increasing levels of superoxide anion (O2•–) and hydrogen peroxide 
(H2O2) (188).
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The ESR in combination with spin trapping method has revealed that ethanol 
oxidation results mainly (more than 80%) in the formation of a free radical identified 
as 1-hydroxylethyl radical (HER) (189). HER have shown to have a high reactivity 
towards ascorbic acid, GSH, D-tocopherol and DNA (Nakao and Augusto et al 1998, 
Stoyanovsky et al 1998). The elevation of oxidized LDL, advanced glyoxidation end 
products and acetaldehyde protein adducts have been observed in heavy alcoholic 
drinkers (188). A decrease level of GSH in liver has been observed both in ethanol 
fed animals as well as patients with alcoholism (188;190) . Lower levels of D-
tocopherol in plasma and liver have been observed in humans and rodents after 
chronic alcohol intake, and the lowering of the D-tocopherol is inversely correlated 
with the detection of lipid peroxidation markers (190). The enteral alcohol model has 
shown a marked decline in enzymatic activity and protein concentrations of various 
enzymes involved in antioxidant defence (190). 
Thus, alcohol abuse also increases oxidative stress. 
There is a strong association between heavy alcohol use and cigarette smoking. 
More than 80% of alcohol dependent patients are reported to smoke cigarettes 
(191;192). In head and neck cancer patients, the combined effect of high alcohol 
consumption in current smokers is more than additive indicating a positive synergy 
(91;173).
1.5.2 Diet and HNSCC 
Although smoking and drinking are the major risk factors for developing HNSCC, 
diet rich in fruits and vegetables have also shown to play an important role. The role 
of diet on the development and risk of HNSCC has been studied extensively. 
Recently the report from WCRF (91)  have clearly indicated that non-starchy 
vegetables, fruits and food rich in carotenoids probably protect against mouth, 
pharynx, larynx and lung cancer. Meta-analysis and several review articles also 
conclude that the consumption of fruit and vegetables is associated with a reduced 
risk of oral and pharyngeal cancer (64;65;193). The preventive effect of fruits and 
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vegetables is also seen in smokers, drinkers and those with both smoking and 
drinking habits (194). Other dietary factors apart from fruits and vegetables like meat, 
saturated fat have shown to increase the risk of HNSCC but the results are still 
inconclusive (91).
The mechanisms behind the protective effect of fruits and vegetables are not fully 
understood as described earlier. Probable mechanisms are their antioxidant role, 
modulation of carcinogenic metabolism, affecting cell transformation and 
differentiation, inhibition of cell proliferation and oncogene expression. 
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2. Study aims  
This work is part of a project where the overall goal is to explore which biomarkers 
of antioxidant defence and oxidative stress are associated with survival in HNSCC 
patients; and can diet rich in fruits and vegetables, modulating these biomarkers, 
improve survival in these patients. This study particularly has focussed on the low 
molecular weight plasma endogenous and dietary antioxidants.
The specific aims are 
x to develop and evaluate improved sensitive chromatographic techniques for 
measuring plasma GSH and GSSG 
x to establish which food groups contribute to the total antioxidant intake in 
Norwegian healthy individuals and to study whether intake of dietary 
antioxidants correlates with low molecular weight plasma antioxidants. 
x to study which low molecular weight plasma antioxidants are affected by 
radiotherapy and their association with survival in HNSCC patients 
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3. Summary of papers 
Paper I: Simultaneous quantification of reduced and oxidized glutathione in 
plasma using a two dimensional chromatographic system with parallel porous 
graphitized carbon columns coupled with fluorescence and coulometric 
electrochemical detection 
In Paper I, a fully validated, accurate and precise chromatographic method for the 
simultaneous quantification of GSH and GSSG in human plasma was developed. The 
developed method avoids artificial oxidation and degradation of GSH during sample 
preparation. In order to achieve this, we have used the commercially available 
Stabilyte tubes to generate plasma from blood. The special feature of these tubes is 
that the anticoagulant is acidic citrate resulting in a final plasma pH of 5.3, thereby 
stabilizing GSH and avoiding oxidation of GSH during plasma formation. After 
blood collection, serine borate buffer was immediately added to inhibit GGT. The 
buffer also contains bathophenanthroline disulphonate (BPDS) to chelate metal ions 
that otherwise can catalyze oxidation of GSH. In addition, we block the very reactive 
–SH group of GSH within 2 min after plasma generation with monobromobimane 
(MBB) to stop unwanted formation of disulphides. GSH bound to MBB, GSMBB, 
was detected with a fluorescence detector (FLD). GSSG was detected with an 
electrochemical detector (ED) optimized to provide lowest possible limits of 
detection (LOD). By combining both FLD and ED via column switching, we were 
able to detect both GSH and GSSG in a single run. The derivatized samples were 
stable up to 8 months in -80qC. A HypercarbTM column that does not require ion pair 
reagent for the retention of GSSG under reversed phase conditions was used. The 
column is stable in the pH range of 1-14 such that 100 μl of strong acidic supernatant 
could be injected without any column deterioration.  
Paper II: Simultaneous and robust trace analysis of reduced and oxidized 
glutathione in minute plasma samples using dual mode fluorescence detection 
and column switching HPLC 
70
 In this work we have further developed the method presented in paper I, increasing 
both sensitivity and selectivity such that GSH and GSSG can be analyzed in 50 μL 
human plasma. In cases where blood/plasma volume is quite limited, the assay can 
detect GSH and GSSG in 5 μL plasma if 80% of the sample is injected into the 
HPLC system. The factors causing the oxidation and degradation of GSH during 
sample preparation have been taken care of and were similar as described in paper I. 
The plasma was generated in Stabilyte tubes and the –SH group of GSH was blocked 
with MBB within 2 min of plasma generation. GSH was detected as a MBB 
derivative by FLD. In this method, the GSSG was detected by FLD after on-line 
postcolumn derivatization with ortho-phthalaldehyde (OPA) at a pH of 12.4. The 
important factors involved in derivatization, namely coil volume, OPA concentration 
in mobile phase 2 and coil temperature were optimized to obtain lowest possible 
LOD for GSSG. The sensitivity for GSSG was improved by a factor of 20 as 
compared to method in paper I. The method is fully validated, performs well, is very 
robust for endogenous plasma concentrations of GSSG, and is currently in use for 
determination of GSH, GSSG and its redox potential in different clinical studies. 
Paper III: Intakes of antioxidants in coffee, wine, and vegetables are correlated 
with plasma carotenoids in humans 
The objective of this study was to determine the contribution of various food groups 
to total antioxidant intake, and to assess the correlations of the total antioxidant intake 
from various food groups with plasma antioxidants. We collected 7-d weighed 
dietary records in a group of 61 adults with corresponding plasma samples, and used 
data from a nationwide survey of 2672 Norwegian adults based on an extensive food 
frequency questionnaire (FFQ). No plasma samples were collected in the nationwide 
survey. The total intake of antioxidants was approximately 17 mmol/d with E-
carotene, D-tocopherol, and ascorbic acid contributing <10%. The intake of coffee 
contributed approximately 11.1 mmol or 64%, followed by fruits and berries (1.8 
mmol), tea (1.4 mmol), wine (0.8 mmol), cereals (i.e., all grain containing foods; 0.8 
mmol), and vegetables (0.4 mmol). The strongest correlations between intake of 
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antioxidants from various food groups and plasma antioxidants were for carotenoids; 
tocopherols and thiols showed much lower correlations. The intake of total 
antioxidants was significantly correlated with lutein, zeaxanthin, and lycopene, 
whereas noncoffee antioxidant intake was significantly correlated with plasma lutein 
and E-carotene. Intakes of coffee, wine and vegetables were significantly correlated 
with zeaxanthin, E-carotene and D-carotene respectively. 
Paper IV: Post-radiotherapy plasma total glutathione is associated to outcome in 
patients with head and neck squamous cell carcinoma 
In paper IV, four plasma thiols, namely GSH, cysteine, homocysteine and cysteinyl 
glycine, were measured in healthy controls (n= 51) and head and neck squamous cell 
carcinoma (HNSCC) patients (n= 29). The method employed in present study reduces 
disulphides prior to derivatization and protein precipitation. Thus, the total thiols 
measured in present study included free reduced thiols (TSH), disulphides (TSST), 
mixed disulphides (TSSX) and protein bound disulphides (TSSP). Patients received 
external beam radiation to a dose of 60-70 Gy for 5-7 weeks. The blood samples were 
taken immediately after the end of radiotherapy. Among thiols, total GSH was 
significantly lower and total homocysteine was significantly higher in patients as 
compared to controls. The differences were, however, not significant after adjusting 
for gender, smoking and BMI. The 29 HNSCC patients were followed for 36 months 
after the end of radiotherapy and 14 patients died during this period. Among patients, 
post-radiotherapy plasma total GSH was significantly higher in survivors than in non-
survivors. There were no significant differences between the levels of other thiols 
(total cysteine, homocysteine or cysteinyl-glycine) in these two groups. Plasma total 
GSH was also associated to survival in these patients, and the patients with lowest 
total GSH levels had the lowest overall survival. 
Paper V: Post-radiotherapy plasma lutein, D-carotene and E-carotene are 
positively associated with survival in patients with head and neck squamous cell 
carcinoma.
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The aim of our study was to compare plasma dietary antioxidants, namely 
tocopherols and carotenoids (i.e. biomarkers of dietary intake of fruits and 
vegetables), in 29 HNSCC patients with 51 healthy controls, and to explore the 
possibility that these antioxidants may be related to survival among HNSCC patients. 
Patients received external beam radiation to a dose of 60-70 Gy for 5-7 weeks. The 
blood samples were taken immediately after the end of radiotherapy. We observed 
that among dietary antioxidants, post-radiotherapy plasma carotenoids (lutein, 
zeaxanthin, D-carotene, E-carotene, lycopene and total) were lower in HNSCC 
patients than controls. Among the patients, 18 died and 11 were still alive during 
median follow-up of 55 months for survivors. The survival analysis showed 
significant positive association of plasma carotenoids (lutein, D-carotene and E-
carotene) with both overall and progression free survival in HNSCC patients. We 
found no significant differences between plasma tocpherols in patients as compared 
to controls. Further, none of the tocopherols were associated to survival in patients. 
This may indicate that increased intake of fruits and vegetables, reflected by plasma 
carotenoids, may reduce risk of premature death or recurrence of tumor in these 
patients.
Paper VI: Pre-radiotherapy plasma carotenoids and markers of oxidative stress 
are associated with survival in head and neck squamous cell carcinoma patients
The aim of this study was to compare plasma levels of antioxidants and markers of 
oxidative stress in HNSCC patients with healthy controls, the effect of radiotherapy 
on these biomarkers and their association to survival in HNSCC patients. Seventy 
eight HNSCC patients were included in this study. Follow-up samples at the end of 
radiotherapy were obtained in 60 patients. The control group comprised of 100 
healthy individuals matched with respect to age range, gender and smoking with 
HNSCC patients. Antioxidants, both endogenous and dietary, and oxidative stress 
markers were measured in plasma samples of controls and patients. Dietary 
antioxidants included 6 carotenoids (lutein, zeaxanthin, E-cryptoxanthin, D-carotene,
E-carotene and lycopene), 4 tocopherols (D-, E-, J- and G-tocopherol) and ascorbic 
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acid. The endogenous antioxidants measured were GSH redox potential, total GSH 
and cysteine. In addition, total antioxidant capacity was measured by FRAP and 
FRAP without uric acid. Among oxidative stress parameters, d-ROMs, GGT, ratio 
oxidized/total ascorbic acid were measured. 
 All dietary antioxidants (carotenoids, tocopherols and ascorbic acid), total 
antioxidant capacity (FRAP, FRAP without uric acid) and total cysteine were 
significantly lower in HNSCC patients as compared to controls and dietary 
antioxidants decreased during radiotherapy. Among oxidative stress biomarkers, d-
ROMs were significantly higher than controls and increased during radiotherapy. 
During the median follow-up time of 28 months for survivors, 23 patients died due to 
HNSCC, one patient died of lung cancer and one patient died of unknown cause. 
Among dietary antioxidants, pre-radiotherapy plasma levels of carotenoids (lutein, E-
cryptoxanthin, E-carotene and total), were positively associated to progression free- 
and overall- survival. No significant associations were observed between pre-
radiotherapy plasma levels of other biomarkers with survival. However, the patients 
with a high relative decrease in plasma levels of FRAP and a high relative increase in 
plasma levels of d-ROMs during radiotherapy had a higher survival rate.
In conclusion, we observed that patients with high pre-radiotherapy plasma 
carotenoids (i.e., biomarkers of fruits and vegetables) are associated with a prolonged 
survival. Further, increase in oxidative stress during treatment also increases survival 
in these patients. Thus, the therapeutic potential of optimizing antioxidant status and 
oxidative stress by increasing intake of fruits and vegetables should be explored 
further.
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4. General discussion 
We have described the average daily intake of antioxidants in the Norwegian healthy 
individuals. It was found that coffee was the major contributor (64-68 %) to the daily 
antioxidant intake in Norwegian diet. The intake of total antioxidants from different 
food groups was significantly correlated with plasma carotenoids. Other plasma 
antioxidants like tocopherols and thiols showed much lower correlations. These 
plasma antioxidants (carotenoids, tocopherols and thiols) were also studied in head 
and neck squamous cell carcinoma (HNSCC) patients, both before and after the end 
of radiotherapy. Among antioxidant biomarkers, several dietary antioxidants were 
found to be significantly lower as compared to healthy controls. HNSCC patients 
receive high dose of radiation therapy. The usual therapeutic radiation dose schedule 
includes 2 Gy/day, 10 Gy/week, for a total of 50-70 Gy in 6 weeks. The plasma 
dietary antioxidants decreased and oxidative stress biomarkers increased significantly 
after the radiotherapy in these patients. Among plasma dietary antioxidants, 
carotenoids, both before and after radiotherapy, were found to be significantly and 
positively associated with survival. Among endogenous antioxidants, post-
radiotherapy plasma total GSH was significantly and positively associated with 
survival. Relative decreases in total antioxidant capacity FRAP and relative increases 
in oxidative stress biomarker d-ROMs during radiotherapy were also significantly 
associated with survival. 
4.1 Methods for assessment of antioxidant and oxidative 
stress status 
There are no single biomarkers available that can define the complete antioxidant and 
oxidative stress status in humans. Thus, a number of biomarkers are measured in 
different sample matrixes to study antioxidant and oxidative stress status both in 
healthy individuals and patients. The feasibility in a clinical study and accuracy in the 
measurement of the chosen biomarkers are important factors. The purpose/aim and 
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the study population in the clinical trials are also deciding factors in choosing the 
biomarker. Our aim was to study antioxidant intake, correlation of antioxidant intake 
to in vivo antioxidants, effect of radiotherapy on in vivo antioxidants and association 
of in vivo antioxidants to survival in HNSCC patients. Thus, we have chosen 
biomarkers that could enlighten these aspects in healthy individuals and patients. All 
the biomarkers were measured in plasma as the status of biomarkers in this biological 
fluid could both reflect the oxidative stress in less accessible tissues and systemic 
oxidative stress in the whole body. Further, the plasma levels of dietary antioxidants 
have shown to be correlated to the intakes of fruits and vegetables (195;196). The 
antioxidants status was studied by measuring both endogenous and dietary 
antioxidants. Among endogenous biomarkers, methods were developed for the 
determination of plasma reduced GSH, GSSG, total GSH and total cysteine. The 
dietary antioxidants are studied by measuring 6 different carotenoids, 4 different 
tocopherols and ascorbic acid. Total antioxidant capacity was measured by FRAP and 
FRAP after removing uric acid. The oxidative stress was studied by measuring d-
ROMs, GGT and ratio oxidized/total ascorbic acid. Not all biomarkers were 
measured in all the clinical studies as some of the methods for the measurement of 
biomarkers were not available and were developed simultaneously.  
4.1.1   Endogenous antioxidants- Glutathione method development 
Reduced and oxidized GSH 
Among endogenous antioxidants, GSH is considered to be one of the major 
nonprotein thiol involved in the antioxidant cellular defence. This tripepetide is 
involved enzymatically in reduction of hydroperoxides and nonenzymatically to 
maintain vitamin E and ascorbic acid in reduced and functional forms (197). In doing 
so GSH is oxidized to GSSG, which is either reduced enzymatically by GR or 
excreted from cells into extracellular fluids. During severe oxidative stress and 
detoxification reactions involving GSH, the concentration of GSH may decrease and 
the concentration of GSSG may increase in the affected cells. This results in a 
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decreased export of GSH and an increased export of GSSG to plasma, thereby 
altering the GSH redox state of the plasma pool. Thus, the altered plasma GSH and 
GSSG concentrations can, thus, reflect GSH/GSSG status and oxidative stress in 
other less accessible tissues (197). Measurement of GSH/GSSG in plasma is not 
straightforward as a number of factors can affect the accuracy in its measurement. 
Sample handling 
 The factors affecting the accuracy in the measurement of GSH include mainly the 
sample handling as shown in paper I. GSH, being an antioxidant, is easily oxidized 
during the centrifugation of whole blood in order to get the plasma. This was clearly 
observed when we used different anticoagulant tubes for the preparation of plasma 
from the whole blood. It was observed that pH of the blood sampling tube was 
important in stopping the oxidation of GSH. The lower the pH the lesser was the 
oxidation. Stabilyte tubes have shown to preserve the ratio of GSH to GSSG as 
compared to tubes containing EDTA, heparin and citrate anticoagulants. The 
anticoagulant used in Stablilyte tubes is acidic citrate such that the pH of the plasma 
prepared from these tubes was 5.3 whereas the pH of the other tubes was 7.4. One 
could suspect that there could be the leakage of GSH from erythrocytes in Stabilyte 
as compared to other tubes as erythrocytes contain 1000 times more GSH than 
plasma. Any leakage of GSH from erythrocytes, either as reduced or oxidized form, 
will increase the total GSH level in plasma as the total GSH measured by the our 
method measures all the forms of GSH after reducing them to GSH. The total GSH 
was similar in all the tubes and we concluded that the high levels of reduced GSH in 
the plasma of Stabilyte were not due to the leakage from erythrocytes. Similar results 
for reduced GSH have been observed by Williams et al. (198). GSSG concentration 
was significantly higher in other anticoagulant tubes as compared to Stabilyte but still 
could not account for the lower GSH concentrations. The reason could be that the 
GSH makes disulphides with cysteine and proteins that we do not measure with this 
method (199-202). 
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Another factor that could affect GSH concentration is the enzyme GGT. GGT cleaves 
GSH at the J-glutamyl bond into amino acid glutamate and dipepetide cysteinyl 
glycine, thereby reducing its concentration. Andersson et al. (203) have shown that 
total GSH was 53 % lower in plasma when GGT was not inhibited. After blood 
collection, serine borate buffer was immediately added to inhibit GGT. The inhibition 
is produced by formation of serine-borate complex which binds at the J-glutamyl
binding site of the light subunit of GGT (204). The serine borate buffer used also 
contained BPDS to chelate metal ions that otherwise can catalyze oxidation of GSH 
(147;148;200).
Thus, the Stabilyte tubes were chosen for the measurement of reduced, oxidized and 
total GSH in plasma in the clinical study presented in paper VI. The clinical studies 
presented in the paper III and IV, however, did not use Stabilyte tubes as the method 
was not completely developed. We have, thus, measured only total GSH in first 
clinical study with HNSCC as total GSH is much more stable in different 
anticoagulants as shown in paper I. 
The blood taken in these tubes could be stored up to 40 min at room temperature 
without any significant increase in the GSH levels.
Detection
After the plasma preparation, the –SH group of GSH was still prone to oxidation as 
the acidification of samples with different acids slows GSH oxidation but it does not 
prevent it completely (149;205). Thus, it was important to block the –SH group of 
GSH in plasma before storage. Since GSH does not contain any native 
spectrophotometric or fluorescence properties we have blocked the –SH group of 
GSH with monobromobimane (MBB). MBB not only blocks the –SH group of GSH 
but it imparts it with the fluorescence properties such that GSH was detected by a 
fluorescence detector with high sensitivity. GSSG also has very poor and non-
specific spectrophotometric or fluorescence properties and the concentration of 
GSSG in plasma is in the nmol/L range. GSSG could be determined either indirectly 
by subtraction method or directly by electrochemical detector (ED) or mass 
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spectrometry (MS) detector. For the indirect method, the GSSG is reduced either 
chemically or enzymatically to GSH. The reduced GSH is then measured by reacting 
it with thiol specific fluorescence probe. The plasma contains different forms of 
bound GSH apart from GSSG, which are also reduced in this process thereby 
reporting higher GSSG concentrations. The concentration of GSSG in plasma is in 
nmol/L and after reduction the increase in reduced GSH is very less which is difficult 
to measure with accuracy. Among the direct methods, GSSG could be measured by 
ED and MS detector. The limit of detection with both detectors is in the pmol range 
as shown in Table 2 in paper II. The ED used in paper I contains an array of 8 
electrochemical cells. The advantage of such a series of cells was that increasing 
potential could be applied to the cells, which will oxidize the impurities in the sample 
matrix and increase the specificity for GSSG. The availability and the price of the 
detector were also deciding factors in choice of the detector. We have, thus, chosen 
ED for detection of GSSG in paper I.
After analyzing plasma samples for GSH and GSSG in other clinical studies, we were 
able to see the limitations with the developed method. The limitations were frequent 
changing of the precolumn/analytical column 1 due to the large injection volume in 
order to reach the required sensitivity for the detection of GSSG. The second 
limitation was the specificity of GSSG in some plasma samples. GSSG being an 
oxidized product requires high electrochemical potential in order to be further 
oxidized. At high potentials, many other compounds in the plasma could be oxidized. 
The series of 8 electrochemical cells used for the detection of GSSG oxidized most of 
the interferences. However, in some plasma samples all the impurities were not 
removed and interfered with the GSSG detection. We have, thus, developed the 
existing method and improved both the sensitivity and specificity for GSSG such that 
injection volume was reduced to 10 μL (paper II). The ED was replaced by an on-line 
postcolumn reactor and a fluorescence detector (FLD). The fluorescence probe used 
in the detection of GSSG was ortho-phthalaldehyde (OPA). OPA is a thiol specific 
fluorescence probe and GSSG usually does not react with these reagents due to lack 
of free –SH group. Cohn and Lyle (206) reported for the first time that GSSG reacted 
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with OPA at a very high pH, namely 12. Hissin and Hilf et al. (207) confirmed the 
results and developed a method for the measurement of GSH and GSSG in a test 
tube. The method suffered with the contamination from other organic compounds in 
the sample as OPA at pH 12 reacted with other compounds besides GSSG. It was 
then suggested to perform a chromatographic separation of GSSG prior to reaction 
with OPA (208). The relative fluorescence intensities of other amino acids like 
glutamic acid, cysteine, cystine, leucine and glycine were less than 1% as compared 
to GSSG thereby showing high specificity of OPA for GSSG at pH 12 (207) . After 
replacing ED with on-line postcolumn reactor and a FLD, several important 
postcolumn reaction parameters, namely coil volume, concentration of OPA in 
mobile phase and temperature for postcolumn reactor were optimized to provide 
lowest possible LOD for GSSG (paper II). The sensitivity for GSSG was, thus, 
improved by a factor of 20 as compared to method in paper I and we were able to 
measure GSH and GSSG simultaneously in 50 μL or less plasma volume. The current 
method was, thus, used for the analysis of plasma GSH and GSSG in paper VI. 
Total Glutathione 
GSH exists in different forms in plasma and blood. The different forms are following: 
reduced GSH, GSH bound to other thiols like cysteine, oxidized form GSSG, GSH 
bound to protein. The distribution of these forms is different in blood and plasma as 
shown by Mills et al. (145) and Mansoor et al. (144). The method for the total GSH 
used in the clinical studies (papers III, IV and VI) includes the reduction of all the 
bounded forms of GSH to the reduced form prior to derivatization and protein 
precipitation. A homocysteine kit was used for the determination of GSH in plasma. 
The commercially available homocysteine kit is validated only for the determination 
of plasma homocysteine but could also be used for the determination of total GSH in 
plasma. Thus, the kit was further validated for the total GSH determination in plasma. 
Different anticoagulants were also tested for the sample collection for total GSH. 
Results have shown that Stabilyte, heparin and EDTA sampling tubes could be used 
for total GSH.
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4.1.2 Dietary antioxidants 
The methods for the determination of dietary antioxidants, namely carotenoids 
(lutein, zeaxanthin, E-cryptoxanthin, D-carotene, E-carotene and lycopene) and 
tocopherols (D-, E-, J- and G-tocopherol) were developed and validated in our 
laboratory.  Different anticoagulants were tested and the results are as follows: For 
carotenoids, EDTA, heparin and serum anticoagulants can be used (data not shown). 
For tocopherols, serum and EDTA anticoagulants are appropriate anticoagulants 
(162). The blood samples from controls and patients in papers IV, V and VI were 
collected in different anticoagulants tubes. The control values were, thus, corrected 
for the appropriate dilution factor due to different volumes of anticoagulants and 
eventual effect of anticoagulants on these biomarkers before statistical analyses. The 
ascorbic acid method was developed by Karlsen et al. (209) and the blood sample 
preparation and analysis was done accordingly as described. FRAP was measured as 
described by Benzie et al. (155) and Halvorsen et al. (210).
4.1.3 Oxidative stress parameters 
The oxidative stress was measured by measuring increase in the d-ROMs, GGT and 
ratio of oxidized/total ascorbic acid. The blood samples for d-ROMs, GGT, oxidized 
ascorbic acid (DHAA) and total ascorbic acid were taken and analyzed that avoided 
any artefact formation.
The biomarkers of DNA, proteins and lipids oxidation were not measured due to 
unavailability of these analytical methods in our laboratory. A large variation in the 
values of these biomarkers has been observed depending upon the method employed 
for measurement (127). Additionally, the type of biomarkers that are representative 
for studying oxidation of DNA, proteins and lipids were not fully established at the 
time of initiation of these studies, such that appropriate sample handling was not 
accomplished either.
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4.2 Sources of antioxidants in healthy Norwegian 
individuals
Among healthy Norwegian individuals, the main dietary contribution to total 
antioxidant intake is coffee (Paper III). These results were observed in 61 individuals 
with 7-day weighed dietary record and were consistent with a much larger nationwide 
survey including 2672 Norwegian adults. The diets in 2672 Norwegian adults were 
characterized using an extensive, self-administered FFQ. The mean daily intake of 
coffee was ca 480 mL and accounted for 64-68 % in both the studies. Although it is 
reported that coffee contains high amount of antioxidants but such a high contribution 
of coffee to antioxidant intake in Norwegian population is not observed before. 
Similar results were observed in a study done by Pulido et al. (211) where coffee 
contributed to 66 % to antioxidant intake in Spanish population. Pellegrini et al. (212) 
have also shown that coffee and tea were the major contributor to antioxidant intake 
in Italian women. 
 Coffee contains several different antioxidants such as caffeine, polyphenols 
including chlorogenic acid (an ester of caffeic acid and quinic acid), volatile aroma 
compounds and various heterocyclic compounds (213). Both caffeic acid and 
chlorogenic acid are absorbed in humans, and plasma antioxidants increase after 
coffee intake (214-216). Epidemiological studies and meta-analysis have also shown 
that coffee is associated with reduced risk of type 2 diabetes, Parkinson disease, 
cirrhosis, liver cancer (217;218). The results showing association between coffee 
intake and risk or mortality due to CVD have not been conclusive (213;217;219). The 
effect of coffee intake in CVD is dependent upon the dose (U-shaped association with 
coffee intake) and type of coffee (filtered, boiled) consumed (213;217;219). In 
conclusion, a moderate intake of 3-5 cups/day filtered coffee could be protective. 
After coffee, fruits and berries were the next contributor to total antioxidant intake. 
Fruits and berries are rich in different polyphenols, carotenoids, vitamins and 
minerals. Intakes of most common dietary antioxidants, namely E-carotene, D-
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tocopherol and ascorbic acid are also shown to be correlated to antioxidant intake 
from fruits and vegetables (paper III).
The correlation of total antioxidant intake from different food groups and plasma 
antioxidants was studied. Among the plasma antioxidants measured, only carotenoids 
(lutein, zeaxanthin, D-carotene, E-carotene and lycopene) showed significant 
correlations. As these 5 carotenoids are only minor contributors to the total intake of 
antioxidants; other dietary antioxidants may theoretically save, recharge or salvage 
these carotenoids when they have been used in a redox reaction in accordance with 
the hypothesis that many antioxidants may interact in a network (95;220). Valtuena et 
al. (221) have also shown that plasma E-carotene is more strongly associated to 
intakes of ascorbic acid and E rather than E-carotene intake itself. The authors 
suggested that it may reflect either sharing of dietary sources (primarily ascorbic 
acid) and/or a protection of plasma E-carotene by other antioxidants. The other 
plasma antioxidants like tocopherols and thiols showed much lower correlations with 
total antioxidant intake from different food groups. These observations might suggest 
that the plasma tocopherols and thiols are not in complete equilibrium with plasma 
carotenoids, which could be due to different chemical reactivities or 
compartmentalization of the plasma pools. Besides, our study included healthy 
individuals having relatively low systemic oxidative stress. Stronger correlations and 
antioxidant networking including tocopherols and thiols might be more important 
and, thus, be observed in clinical situations with prolonged oxidative stress.
Thus, in Norwegian healthy individuals the main contributors to antioxidant intake 
are coffee, fruits and berries. Among different low molecular weight plasma 
antioxidants, carotenoids have shown strongest correlations with total antioxidant 
intake from different food groups.     
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4.3 Plasma antioxidants in head and neck cancer patients 
The assessment of plasma antioxidants in HNSCC patients were studied in two 
clinical studies 1 and 2. The first was a pilot study with 29 HNSCC patients and 51 
healthy controls. The patients received external beam radiotherapy to a total dose of 
60-70 Gy during the treatment period of 5-7 weeks (papers IV and V). The main 
purpose of this study was to investigate how the plasma antioxidants status of the 
patients after the end of radiotherapy and being cured of cancer was associated to 
survival. Hence, post-radiotherapy blood sample were taken at two different time 
points, immediately after the end of radiotherapy and 6-weeks after the end of 
radiotherapy. The levels were compared to healthy controls. In the clinical study 2 
(paper VI), we wanted to find out how radiotherapy affects the plasma antioxidant 
levels and how pre-radiotherapy plasma antioxidant status is related to survival in 
these patients. This information is quite important since it is speculated that the 
adverse effects of radiotherapy could be reduced by giving antioxidants to the 
patients during the radiotherapy. The purpose of radiotherapy is to kill the cancer by 
increasing the amount of free radicals. The antioxidant supplementation during 
radiation therapy poses a conundrum for the radiation oncologist, as antioxidants that 
protect normal cells from reactive oxygen species may provide the same benefits to 
cancer cells and reduce the efficacy of treatment (222;223). Thus, it is quite important 
to know what actually happens to plasma endogenous and dietary antioxidants before 
and after radiotherapy and how these antioxidants are related to survival in these 
patients. Hence, in the second clinical study 78 patients were included and blood 
samples were taken both before and after the end of the radiotherapy. Patients in this 
study also received a total dose of 50-70 Gy for 5-7 weeks.
The populations in both the studies were quite similar with respect to the type of 
cancer, age and radiation therapy dose. However, the study presented in paper VI had 
more men and non-smokers; more patients received assisted enteral nutrition and 
were operated before radiotherapy as shown in Table 4. The assisted nutrition 
received by patients in the clinical study 2 was also fortified with E-carotene (130 
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μg/100 mL) whereas the assisted nutrition given to patients in the first clinical study 
did not contain any carotenoids. 
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Table 4 Different basic parameters in clinical studies 1 and 2. In the first clinical 
study, only post-radiotherapy samples were available whereas in the second 
clinical study both pre- and post- radiotherapy samples were taken.
Variables Study 1 (paper 
IV and V) 
Post-
radiotherapy
n = 29 
Study 2 
(paper VI) 
Post-
radiotherapy
n = 60 
Study 2 (paper 
VI)
Pre-
radiotherapy
n = 78
Age (years)* 64 (43-90)  62 (37-85) 63 (34-85) 
BMI* 24 (17-31) 25 (16-40) 25 (16-40) 
Male 22 (76%) 56 (93%) 69 (88%) Gender
Female 7 4 9 
Non-smoker 6 (23%) 25 (42%) 28 (36%) Smoking status 
Smoker 20 35 50 
Stage 1 and 2 7 (24%) 20 (33%) 26 (33%) Disease stage 
Stage 3 and 4 22 40 52 
Surgery before 
radiotherapy
6 (21%) 22 (37%) 30 (39%) Treatment 
Radiotherapy 23 38 48 
Assisted
nutrition
8 (28%) 24 (40%) 24 (40%) Nutrition form 
Oral diet 21 36 36 
* Values are presented as median (range) 
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4.3.1 Dietary antioxidants 
Plasma levels, effect of radiotherapy and survival 
The levels of pre- and post- radiotherapy plasma dietary antioxidants in HNSCC 
patients were compared to healthy controls (papers V and VI). The levels of several 
pre-radiotherapy dietary antioxidants including carotenoids were significantly lower 
in HNSCC patients than matched controls as shown in paper VI. This could be due to 
low intake of fruits and vegetables and other life style factors including smoking. 
Reports have also shown that low intakes of fruits and vegetables (91;193), low 
dietary intakes of carotenoids (194;224) and lower pre-diagnostic plasma E-carotene
levels (225;226) are associated with increased risk of developing HNSCC. Post-
radiotherapy antioxidants were also significantly lower than controls as shown in 
paper V. Since the blood samples in paper V were taken at the end of radiotherapy, 
lower levels of the antioxidants in patients could be due to other additional factors 
such as (1) eating problems due to the adverse effects of radiotherapy and (2) 
utilization of antioxidants during radiotherapy. After correcting either for various 
confounding factors such as BMI (representing food intake and physical activity), 
smoking and age or using matched controls, the results were still significant for 
carotenoids. This indicates that the food intake did not account for the observed 
difference. A low intake of fruits and vegetables both before and during the 
radiotherapy seems to be the most plausible explanation for the lower carotenoid 
plasma levels in patients. Steward et al. (227) have also shown that the patients that 
have been treated for early-stage oral cavity carcinoma and are free of cancer have a 
much lower mean daily intake of fruits and vegetables and dietary antioxidants than 
matched controls.  
In paper VI, we have further studied the effect of radiotherapy on these antioxidants. 
During radiotherapy we observed a significant decline in plasma levels of 
carotenoids, tocopherols and ascorbic acid. Among carotenoids, E-carotene showed a 
non-significant decrease (p = 0.4). In paper VI, 24 patients received assisted enteral 
nutrition fortified with E-carotene (130 μg/ml). Subgroup analysis in patients without 
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assisted enteral nutrition revealed a borderline decline also for E-carotene (p = 0.06). 
It has also been shown that the half-lives of serum carotenoids during depletion 
(intake of low carotenoid diet) are 4-11 weeks (228). Thus, the decrease in plasma 
carotenoids during radiotherapy (a period of 5-7 weeks) could be due to low intake of 
fruits and vegetables during treatment period and utilization of these antioxidants 
during that period.
The survival was studied with both post-radiotherapy (paper V) and pre-radiotherapy 
plasma antioxidant levels (paper VI). Our results showed that among dietary 
antioxidants, 3 post-radiotherapy plasma carotenoids (lutein, D-carotene and E-
carotene) were significantly and positively associated with survival in these patients 
after correcting for BMI (paper V). None of the tocopherols were associated to 
survival. These 3 carotenoids were also found to be most reliable for assessing 
changes in fruit and vegetable intakes (229-235). Paper III has also shown that 
antioxidant intake in different food groups is correlated to plasma carotenoids and not 
tocopherols in healthy individuals. Since the patients have lower intake of fruits and 
vegetables as reflected through their plasma carotenoid levels and data shown 
elsewhere (227;236), we suggest that increasing the intake of this food group may 
reduce risk of premature death or recurrence of tumor in HNSCC patients. 
 In paper VI, we have explored how the pre-radiotherapy plasma levels are associated 
to survival. Results have shown that plasma carotenoids (lutein, E-carotene and E-
cryptoxanthin and total) are significantly and positively associated to survival. Other 
dietary antioxidants such as tocopherols and ascorbic acid have shown no significant 
associations with the survival. Recent report from WCRF has also concluded that 
foods containing carotenoids probably protect against mouth, pharynx, larynx and 
lung cancer (91). In elderly subjects the plasma carotene concentration was associated 
with a lower overall mortality risk (70). This risk was also observed for both cancer 
and cardiovascular mortality. Unlike our study, Mayne et al. (237) has shown that 
among carotenoids, only plasma lycopene is associated to overall survival in early 
stage head and neck cancer patients. The study population was, however, different 
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from our study as one of the inclusion criteria in the study was that the patients had 
completed their treatment and considered free of cancer at any site. Hence, many 
deaths related to treatment toxicity and other causes were not recorded.
In conclusion, plasma levels of both pre- and post- radiotherapy carotenoids 
(biomarkers of fruits and vegetables) in HNSCC patients are lower than healthy 
controls, decrease during radiotherapy and have shown positive associations with 
overall and progression free survival.
4.3.2 Endogenous antioxidants 
Plasma levels, effect of radiotherapy and survival 
Among endogenous antioxidants, we measured plasma GSH in papers IV and VI. In 
paper IV the method for the determination of both reduced and oxidized was not 
available and thus we have only measured plasma total GSH. Both in papers IV and 
V, the total GSH was not significantly lower in patients as compared to healthy 
controls. The post-radiotherapy plasma levels of total GSH measured in HNSCC 
patients in paper VI (mean total GSH = 5.63 μM) were, however, higher than those in 
paper IV (mean total GSH = 3.68 μM) showing that the patients in the paper VI have 
a better endogenous antioxidant status. In both papers, same method for the analysis 
of total GSH is employed. The reason for better plasma GSH status of patients in the 
clinical study 2 could be due to following reasons. In the clinical study 2 there were 
fewer smokers, fewer advanced stage (III and IV) patients and more patients received 
assisted nutrition as compared to study 1. Additionally, more patients in clinical study 
2 were operated before radiotherapy as compared to clinical study 1. The 
postoperative radiotherapy has shown to have a significant positive association with 
both progression free- and overall- survival, log rank p = 0.03 and 0.005, 
respectively. Thus, patients in clinical study 2 were better followed up as compared to 
patients in study 1. Another reason for high total GSH concentration in paper VI 
could be that plasma in clinical study 2 was collected in Stabilyte tubes and serine 
borate buffer that inhibits the enzyme gamma glutamyl transpeptidase (GGT) was 
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added. The enzyme GGT cleaves GSH thereby reducing its concentration in samples. 
Serine borate binds GGT thereby inhibiting its activity.
The effect of radiotherapy on plasma GSH redox potential and total GSH was studied 
in paper VI. Although dietary antioxidants decreased significantly after radiotherapy, 
we observed no decrease in endogenous antioxidants. Similar results are shown by 
Mukndan et al. (238) and Bhuvarahamurthy et al. (239) where they have studied 
plasma reduced GSH before and after radiation therapy in uterine cervix cancer 
patients. However, Jadhav et al. (240) have shown decreased levels of plasma 
GSH+GSSG after one fraction of radiation therapy in cervix cancer. This difference 
could be due to the fact that they measured GSH+GSSG only after one fraction of 
radiation therapy and not after completing the whole treatment.
The association of plasma GSH levels with survival is studied in papers IV and VI. 
Paper IV has shown that the patients with post-radiotherapy plasma total GSH levels 
over median has longest overall survival rate. The pre-radiotherapy GSH redox 
potential and total GSH have shown no association with survival in paper VI. 
4.3.3 Total antioxidant capacity (TAC) 
Plasma levels, effect of radiotherapy and survival 
Plasma TAC was measured by FRAP and FRAP without uric acid (paper VI). Uric 
acid accounts for about 60 % antioxidant capacity in FRAP (155). The roles of uric 
acid as an antioxidant is still inconclusive and thus we have measured both FRAP and 
FRAP without uric acid. Both FRAP and FRAP without uric acid were significantly 
lower in HNSCC patients than healthy controls. However, none of them decreased 
significantly during radiotherapy. Similar effect of radiotherapy on TAC measured by 
TRAP was shown by Erhola et al. (241) in lung cancer patients. To our knowledge no 
data is available showing effect of radiotherapy on TAC in HNSCC patients. Pre-
radiotherapy plasma TAC was not associated with survival. However, relative 
decreases in FRAP showed a positive association with survival. The effect could be 
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due to decrease in uric acid levels as FRAP without uric acid showed a borderline 
association with survival (HR 0.53, 95 % CI 0.23-1.21, p = 0.13).
4.3.4 Oxidative stress biomarkers 
Plasma levels, effect of radiotherapy and survival 
The oxidative stress biomarkers measured in plasma were d-ROMs, GGT and ratio 
oxidized/total ascorbic acid (paper VI). d-ROMs were significantly higher in patients 
as compared to controls and increased significantly during radiotherapy also. Another 
marker of oxidative stress GGT also increased significantly during radiotherapy. We 
observed no significant association between pre-radiotherapy plasma levels of 
markers of oxidative stress and survival. However, a high relative increase in d-
ROMs during radiotherapy was significantly and positively associated with survival 
in patients. These results indicate that the patients that are responding to radiotherapy 
and increase oxidative stress during treatment have a prolonged survival. Thus, care 
must be taken if antioxidant administration is considered during the treatment period.  
4.4 Future perspectives   
We measured dietary antioxidants with different chemical properties in order to study 
their association with antioxidant intake in healthy subjects and with survival in 
HNSCC patients. The results show that plasma carotenoids were significantly 
associated to total antioxidant intake from different food groups in healthy 
individuals and were positively associated to survival in HNSCC patients. Among 
endogenous antioxidants, we have studied only glutathione and found no strong 
associations. Thus, other endogenous antioxidants like different enzymes involved in 
antioxidant defence like superoxide dismutase, catalase, glutathione peroxidase and 
glutathione reductase could be studied in this population.
Since plasma carotenoids (biomarkers of fruits and vegetables) have shown strongest 
effects in our studies, intervention trials with increasing fruits and vegetables intake 
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in these patients at an appropriate timing and studying survival could be conducted. 
This group of patients suffer from a lot of eating problems and thus intervention in 
the form of juice or soups could be suggested. Nutritional counselling, especially 
during the treatment period will motivate the patients to maintain their fruit and 
vegetable intake and thus should be integrated in the regular treatment schedule. 
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5. Conclusions 
x A sensitive and specific chromatographic method for the simultaneous 
determination of GSH and GSSG in plasma using dual mode fluorescence 
detection has been developed. Use of Stabilyte blood sampling tubes for 
plasma preparation, inhibition of GGT and blocking the –SH group of GSH 
with monobromobimane, are important factors for maintaining GSH and 
GSSG ratio in plasma. The specificity and sensitivity of this assay allows 
analysis after fingertip sampling, blood sampling from infants or multiple 
blood sampling from experimental animals without sacrificing the animal. 
x Coffee intake, followed by fruits and berries are the major contributors to 
antioxidant intake in healthy Norwegian individuals. Several plasma 
carotenoids are correlated to total antioxidant intake (FRAP) by different food 
groups (coffee, tea, wine, cereal, fruits and vegetables).
x In HNSCC patients, both pre- and post- radiotherapy plasma carotenoids were 
significantly lower in patients compared to healthy controls. All plasma 
dietary antioxidants (carotenoids, tocopherols and ascorbic acid) decreased 
significantly during radiotherapy. No effect of radiotherapy was observed on 
endogenous antioxidants. Oxidative stress, measured by d-ROMs and GGT 
increased significantly during radiotherapy. Among the different antioxidants 
measured, pre-radiotherapy plasma carotenoids have shown strongest positive 
association with survival in these patients. Additionally, the relative increases 
in plasma levels of d-ROMs and relative decreases in plasma levels of total 
antioxidant capacity (FRAP) during radiotherapy were also associated with a 
prolonged survival in these patients. 
x Our data show that high levels of both pre- and post- radiotherapy plasma 
carotenoids are beneficial for survival in HNSCC patients. Plasma carotenoids 
are biomarkers of fruits and vegetable intake. This may suggest that HNSCC 
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patients should be advised to increase their intake of fruits and vegetables rich 
in carotenoids, both before and after radiotherapy. However, since a reduced 
risk of disease relapse was observed in individuals experiencing a greater 
degree of oxidative stress during treatment period, our data may suggest that 
administration of antioxidants should not be combined with radiotherapy. The 
effects of carotenoid-rich fruits and vegetables before, during and after the 
radiotherapy on survival in HNSCC patients should be studied in future 
intervention trials.
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